

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
19 February 2004 (19.02.2004)

PCT

(10) International Publication Number
WO 2004/014299 A2

(51) International Patent Classification⁷: **A61K**
(21) International Application Number:
PCT/US2003/023886
(22) International Filing Date: 31 July 2003 (31.07.2003)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
10/210,833 31 July 2002 (31.07.2002) US
(71) Applicant: **ISIS PHARMACEUTICALS, INC.**
[US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008
(US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors: **BHANOT, Sanjay**; 7965 Paseo Aliso, Carlsbad, CA 92009 (US). **FREIER, Susan, M.**; 2946 Renault Street, San Diego, CA 92122 (US).
(74) Agent: **WILLIAMS, Joseph, A.**; Marshall, Gerstein & Borun LLP, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606 (US).

Published:

— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTISENSE MODULATION OF RESISTIN EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of resistin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding resistin. Methods of using these compounds for modulation of resistin expression and for treatment of diseases associated with expression of resistin are provided.



WO 2004/014299 A2

RTS--0396

-1-

PATENT

5 **ANTISENSE MODULATION OF RESISTIN EXPRESSION****FIELD OF THE INVENTION**

10 The present invention provides compositions and methods for modulating the expression of resistin. In particular, this invention relates to compounds, particularly oligonucleotides, specifically hybridizable with nucleic acids encoding resistin. Such compounds have been shown to
15 modulate the expression of resistin.

BACKGROUND OF THE INVENTION

Insulin resistance is defined as a failure of target tissues (adipose, liver, skeletal and cardiac muscle) to
20 respond normally to insulin. At the molecular level, this resistance can occur anywhere in the insulin signaling pathway, from receptor-binding to downstream signaling events. Obesity-associated insulin resistance is manifested by increased hepatic glucose output and reduced glucose
25 disposal in peripheral tissues. Quantitatively, skeletal muscle is the most important site of insulin-mediated glucose disposal. Adipose tissue clearly plays a significant role in the pathogenesis of insulin resistance, as shown by the high correlation between obesity and insulin resistance. Obesity-
30 induced insulin resistance is affected both by the total amount of adipose tissue and its distribution. Both visceral and deep subcutaneous adipose tissues are associated with insulin resistance.

RTS-0396

-2-

PATENT

Excessive free fatty acids (FFAs) released by lipolysis from adipose tissue have been implicated in non-insulin dependent diabetes mellitus. FFAs have a deleterious effect on insulin uptake by the liver and contribute to the increased hepatic glucose release. The observation that adipose-specific changes in gene expression alter insulin sensitivity in muscle and liver in the mouse reinforces the concept that signals emanating from adipose tissue regulate glucose homeostasis (Steppan and Lazar, *Trends Endocrinol Metab*, **2002**, 13, 18-23).

Resistin, a gene named for its role in insulin resistance, is also known as FIZZ3 (found in inflammatory zone 3). It was identified and localized to chromosome 19p13.3 (Kim et al., *J. Biol. Chem.*, **2001**, 276, 11252-11256; Steppan et al., *Nature*, **2001**, 409, 307-312).

An isolated nucleic acid sequence encoding a mammalian resistin is disclosed and claimed in PCT publication WO 00/64920 (Lazar, **2000**). Resistin mRNA, which encodes a 114-amino acid polypeptide containing a 20-amino acid signal sequence, is induced during 3T3-L1 adipogenesis of white adipose tissue in both the mouse and rat. The highest levels of expression are observed in female gonadal adipose tissue (Steppan and Lazar, *Trends Endocrinol Metab*, **2002**, 13, 18-23).

Investigations of resistin expression in human adipocytes have indicated that the increased resistin expression observed in abdominal fat, relative to other types of adipose tissue, may explain the increased risk of type 2 diabetes associated with central obesity (McTernan et al., *Lancet*, **2002**, 359, 46-47).

Regulators of resistin have been employed in investigations of its biological roles. Steppan et al. have found that circulating resistin levels are decreased by the anti-diabetic drug rosiglitazone (a member of the thiazolidinedione class of class of anti-diabetic drugs) and increased in diet-induced and genetic forms of obesity in mice. In addition, treatment of normal mice with recombinant

RTS-0396

-3-

PATENT

resistin impairs glucose tolerance and insulin action. The conclusion of this study is that resistin is a hormone that potentially links obesity to diabetes (Steppan et al., *Nature*, **2001**, 409, 307-312).

5 Expression levels of resistin in mice and in 3T3-L1 adipocytes have been found to be induced by beta-3 adrenergic agonists and down-regulated by tumor necrosis factor-alpha and isoproterenol (Fasshauer et al., *FEBS Lett.*, **2001**, 500, 60-63; Fasshauer et al., *Biochem. Biophys. Res. Commun.*,
10 **2001**, 288, 1027-1031; Martinez et al., *J. Physiol. Biochem.*, **2001**, 57, 287-288).

The potential involvement of resistin in insulin resistance indicates that it may prove to be a useful target for therapeutic intervention in type 2 diabetes and/or other
15 disorders related to obesity.

Disclosed and claimed in PCT publication WO 00/64920 is an anti-diabetic composition comprising a pharmaceutically acceptable carrier and an isolated nucleic acid sequence complementary to said mammalian resistin sequence, in the
20 antisense direction, and a method of alleviating type 2 diabetes via administration of said anti-diabetic composition to a patient afflicted with type 2 diabetes (Lazar, **2000**).

Currently, there are no known therapeutic agents that effectively inhibit the synthesis of resistin. To date,
25 investigative strategies aimed at modulating resistin expression have involved the use of rosiglitazone, beta-3 adrenergic agonists, tumor necrosis factor-alpha and isoproterenol. Consequently, there remains a long felt need for additional agents capable of effectively inhibiting
30 resistin function.

Antisense technology is emerging as an effective means for reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications for the
35 modulation of expression of resistin.

The present invention provides compositions and methods for modulating expression of resistin.

RTS-0396

-4-

PATENT

SUMMARY OF THE INVENTION

The present invention is directed to compounds,
5 particularly antisense oligonucleotides, which are targeted
to a nucleic acid encoding resistin, and which modulate the
expression of resistin. Pharmaceutical and other
compositions comprising the compounds of the invention are
also provided. Further provided are methods of modulating
10 the expression of resistin in cells or tissues comprising
contacting said cells or tissues with one or more of the
antisense compounds or compositions of the invention.
Further provided are methods of treating an animal,
particularly a human, suspected of having or being prone to a
15 disease or condition associated with expression of resistin
by administering a therapeutically or prophylactically
effective amount of one or more of the antisense compounds or
compositions of the invention.

20 DETAILED DESCRIPTION OF THE INVENTION

The present invention employs oligomeric compounds,
particularly antisense oligonucleotides, for use in
modulating the function of nucleic acid molecules encoding
resistin, ultimately modulating the amount of resistin
25 produced. This is accomplished by providing antisense
compounds which specifically hybridize with one or more
nucleic acids encoding resistin. As used herein, the terms
"target nucleic acid" and "nucleic acid encoding resistin"
encompass DNA encoding resistin, RNA (including pre-mRNA and
30 mRNA) transcribed from such DNA, and also cDNA derived from
such RNA. The specific hybridization of an oligomeric
compound with its target nucleic acid interferes with the
normal function of the nucleic acid. This modulation of

RTS-0396

-5-

PATENT

function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translocation of the RNA to sites within the cell which are distant from the site of RNA synthesis, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of resistin. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding resistin. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a

RTS-0396

-6-

PATENT

preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in
5 transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and
10 5'-AUA, 5'-ACG and 5'-CUG have been shown to function *in vivo*. Thus, the terms "translation initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in
15 prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of
20 the invention, "start codon" and "translation initiation codon" refer to the codon or codons that are used *in vivo* to initiate translation of an mRNA molecule transcribed from a gene encoding resistin, regardless of the sequence(s) of such codons.

25 It is also known in the art that a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and
30 "translation initiation codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the

RTS-0396

-7-

PATENT

terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation
5 termination codon.

The open reading frame (ORF) or "coding region," which is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively.

10 Other target regions include the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding
15 nucleotides on the gene, and the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding
20 nucleotides on the gene. The 5' cap of an mRNA comprises an N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent
25 to the cap. The 5' cap region may also be a preferred target region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is
30 translated. The remaining (and therefore translated) regions are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are

RTS-0396

-8-

PATENT

particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. mRNA transcripts produced via the process of splicing of two (or more) mRNAs from different gene sources are known as "fusion transcripts". It has also been found that introns can be effective, and therefore preferred, target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

It is also known in the art that alternative RNA transcripts can be produced from the same genomic region of DNA. These alternative transcripts are generally known as "variants". More specifically, "pre-mRNA variants" are transcripts produced from the same genomic DNA that differ from other transcripts produced from the same genomic DNA in either their start or stop position and contain both intronic and extronic regions.

Upon excision of one or more exon or intron regions or portions thereof during splicing, pre-mRNA variants produce smaller "mRNA variants". Consequently, mRNA variants are processed pre-mRNA variants and each unique pre-mRNA variant must always produce a unique mRNA variant as a result of splicing. These mRNA variants are also known as "alternative splice variants". If no splicing of the pre-mRNA variant occurs then the pre-mRNA variant is identical to the mRNA variant.

It is also known in the art that variants can be produced through the use of alternative signals to start or stop transcription and that pre-mRNAs and mRNAs can possess more than one start codon or stop codon. Variants that originate from a pre-mRNA or mRNA that use alternative start codons are known as "alternative start variants" of that pre-

RTS-0396

-9-

PATENT

mRNA or mRNA. Those transcripts that use an alternative stop codon are known as "alternative stop variants" of that pre-mRNA or mRNA. One specific type of alternative stop variant is the "polyA variant" in which the multiple transcripts
5 produced result from the alternative selection of one of the "polyA stop signals" by the transcription machinery, thereby producing transcripts that terminate at unique polyA sites.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently
10 complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or
15 reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary," as used herein, refers to the capacity for precise pairing between
20 two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that
25 position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms
30 which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the

RTS-0396

-10-

PATENT

sequence of an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable.

An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed. It is preferred that the antisense compounds of the present invention comprise at least 80% sequence complementarity to a target region within the target nucleic acid, moreover that they comprise 90% sequence complementarity and even more comprise 95% sequence complementarity to the target region within the target nucleic acid sequence to which they are targeted. For example, an antisense compound in which 18 of 20 nucleobases of the antisense compound are complementary, and would therefore specifically hybridize, to a target region would represent 90 percent complementarity. Percent complementarity of an antisense compound with a region of a target nucleic acid can be determined routinely using basic local alignment search tools (BLAST programs) (Altschul et al., *J. Mol. Biol.*, **1990**, 215, 403-410; Zhang and Madden, *Genome Res.*, **1997**, 7, 649-656).

Antisense and other compounds of the invention, which hybridize to the target and inhibit expression of the target, are identified through experimentation, and representative sequences of these compounds are hereinbelow identified as preferred embodiments of the invention. The sites to which

RTS-0396

-11-

PATENT

these preferred antisense compounds are specifically hybridizable are hereinbelow referred to as "preferred target regions" and are therefore preferred sites for targeting. As used herein the term "preferred target region" is defined as at least an 8-nucleobase portion of a target region to which an active antisense compound is targeted. While not wishing to be bound by theory, it is presently believed that these target regions represent regions of the target nucleic acid which are accessible for hybridization.

10 While the specific sequences of particular preferred target regions are set forth below, one of skill in the art will recognize that these serve to illustrate and describe particular embodiments within the scope of the present invention. Additional preferred target regions may be identified by one having ordinary skill.

15 Target regions 8-80 nucleobases in length comprising a stretch of at least eight (8) consecutive nucleobases selected from within the illustrative preferred target regions are considered to be suitable preferred target regions as well.

Exemplary good preferred target regions include DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 5'-terminus of one of the illustrative preferred target regions (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately upstream of the 5'-terminus of the target region and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). Similarly good preferred target regions are represented by DNA or RNA sequences that comprise at least the 8 consecutive nucleobases from the 3'-terminus of one of the illustrative preferred target regions (the remaining nucleobases being a consecutive stretch of the same DNA or RNA beginning immediately downstream of the 3'-terminus of

RTS-0396

-12-

PATENT

the target region and continuing until the DNA or RNA contains about 8 to about 80 nucleobases). One having skill in the art, once armed with the empirically-derived preferred target regions illustrated herein will be able, without undue experimentation, to identify further preferred target regions. In addition, one having ordinary skill in the art will also be able to identify additional compounds, including oligonucleotide probes and primers, that specifically hybridize to these preferred target regions using techniques available to the ordinary practitioner in the art.

Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

For use in kits and diagnostics, the antisense compounds of the present invention, either alone or in combination with other antisense compounds or therapeutics, can be used as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of genes expressed within cells and tissues.

Expression patterns within cells or tissues treated with one or more antisense compounds are compared to control cells or tissues not treated with antisense compounds and the patterns produced are analyzed for differential levels of gene expression as they pertain, for example, to disease association, signaling pathway, cellular localization, expression level, size, structure or function of the genes examined. These analyses can be performed on stimulated or

RTS-0396

-13-

PATENT

unstimulated cells and in the presence or absence of other compounds which affect expression patterns.

Examples of methods of gene expression analysis known in the art include DNA arrays or microarrays (Brazma and Vilo, *FEBS Lett.*, **2000**, 480, 17-24; Celis, et al., *FEBS Lett.*, **2000**, 480, 2-16), SAGE (serial analysis of gene expression) (Madden, et al., *Drug Discov. Today*, **2000**, 5, 415-425), READS (restriction enzyme amplification of digested cDNAs) (Prashar and Weissman, *Methods Enzymol.*, **1999**, 303, 258-72), TOGA (total gene expression analysis) (Sutcliffe, et al., *Proc. Natl. Acad. Sci. U. S. A.*, **2000**, 97, 1976-81), protein arrays and proteomics (Celis, et al., *FEBS Lett.*, **2000**, 480, 2-16; Jungblut, et al., *Electrophoresis*, **1999**, 20, 2100-10), expressed sequence tag (EST) sequencing (Celis, et al., *FEBS Lett.*, **2000**, 480, 2-16; Larsson, et al., *J. Biotechnol.*, **2000**, 80, 143-57), subtractive RNA fingerprinting (SuRF) (Fuchs, et al., *Anal. Biochem.*, **2000**, 286, 91-98; Larson, et al., *Cytometry*, **2000**, 41, 203-208), subtractive cloning, differential display (DD) (Jurecic and Belmont, *Curr. Opin. Microbiol.*, **2000**, 3, 316-21), comparative genomic hybridization (Carulli, et al., *J. Cell Biochem. Suppl.*, **1998**, 31, 286-96), FISH (fluorescent in situ hybridization) techniques (Going and Gusterson, *Eur. J. Cancer*, **1999**, 35, 1895-904) and mass spectrometry methods (reviewed in To, *Comb. Chem. High Throughput Screen*, **2000**, 3, 235-41).

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses. Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotide drugs, including ribozymes, have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus

RTS-0396

-14-

PATENT

established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.

5 In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and
10 covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example,
15 enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.

 While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not
20 limited to oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 80 nucleobases (i.e. from about 8 to about 80 linked nucleosides). Particularly preferred antisense compounds are
25 antisense oligonucleotides from about 8 to about 50 nucleobases, even more preferably those comprising from about 12 to about 30 nucleobases. Antisense compounds include ribozymes, external guide sequence (EGS) oligonucleotides (oligozymes), and other short catalytic RNAs or catalytic
30 oligonucleotides which hybridize to the target nucleic acid and modulate its expression.

 Antisense compounds 8-80 nucleobases in length comprising a stretch of at least eight (8) consecutive

RTS-0396

-15-

PATENT

nucleobases selected from within the illustrative antisense compounds are considered to be suitable antisense compounds as well.

Exemplary preferred antisense compounds include DNA or
5 RNA sequences that comprise at least the 8 consecutive
nucleobases from the 5'-terminus of one of the illustrative
preferred antisense compounds (the remaining nucleobases
being a consecutive stretch of the same DNA or RNA beginning
immediately upstream of the 5'-terminus of the antisense
10 compound which is specifically hybridizable to the target
nucleic acid and continuing until the DNA or RNA contains
about 8 to about 80 nucleobases). Similarly preferred
antisense compounds are represented by DNA or RNA sequences
that comprise at least the 8 consecutive nucleobases from the
15 3'-terminus of one of the illustrative preferred antisense
compounds (the remaining nucleobases being a consecutive
stretch of the same DNA or RNA beginning immediately
downstream of the 3'-terminus of the antisense compound which
is specifically hybridizable to the target nucleic acid and
20 continuing until the DNA or RNA contains about 8 to about 80
nucleobases). One having skill in the art, once armed with
the empirically-derived preferred antisense compounds
illustrated herein will be able, without undue
experimentation, to identify further preferred antisense
25 compounds.

Antisense and other compounds of the invention, which
hybridize to the target and inhibit expression of the target,
are identified through experimentation, and representative
sequences of these compounds are herein identified as
30 preferred embodiments of the invention. While specific
sequences of the antisense compounds are set forth herein,
one of skill in the art will recognize that these serve to
illustrate and describe particular embodiments within the

RTS-0396

-16-

PATENT

scope of the present invention. Additional preferred antisense compounds may be identified by one having ordinary skill.

As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn, the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred. In addition, linear structures may also have internal nucleobase complementarity and may therefore fold in a manner as to produce a double stranded structure. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages. As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art, modified oligonucleotides that do not have a phosphorus atom

RTS-0396

-17-

PATENT

in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotri-
5 esters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates,
10 thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2'
15 to 2' linkage. Preferred oligonucleotides having inverted polarity comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be abasic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts, mixed
20 salts and free acid forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423;
25 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; 5,194,599; 5,565,555; 5,527,899; 5,721,218; 5,672,697 and 5,625,050, certain of which are
30 commonly owned with this application, and each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are

RTS-0396

-18-

PATENT

formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; 5,792,608; 5,646,269 and 5,677,439, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an

RTS-0396

-19-

PATENT

amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States
5 patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., *Science*, **1991**, 254, 1497-1500.

10 Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular -CH₂-NH-O-CH₂-, -CH₂-N(CH₃)-O-CH₂- [known as a methylene (methyylimino) or MMI backbone], -CH₂-O-N(CH₃)-CH₂-, -CH₂-
15 N(CH₃)-N(CH₃)-CH₂- and -O-N(CH₃)-CH₂-CH₂- [wherein the native phosphodiester backbone is represented as -O-P-O-CH₂-] of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having morpholino
20 backbone structures of the above-referenced U.S. patent 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-,
25 S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Particularly preferred are
O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂,
30 and O(CH₂)_nON[(CH₂)_nCH₃]₂, where n and m are from 1 to about 10. Other preferred oligonucleotides comprise one of the following at the 2' position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl,

RTS-0396

-20-

PATENT

O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, **1995**, 78, 486-504) i.e., an alkoxyalkoxy group. A further preferred modification includes 2'-dimethylaminooxyethoxy, i.e., a O(CH₂)₂ON(CH₃)₂ group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethyl-amino-ethoxy-ethyl or 2'-DMAEOE), i.e., 2'-O-CH₂-O-CH₂-N(CH₃)₂, also described in examples hereinbelow.

Other preferred modifications include 2'-methoxy (2'-O-CH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂), 2'-allyl (2'-CH₂-CH=CH₂), 2'-O-allyl (2'-O-CH₂-CH=CH₂) and 2'-fluoro (2'-F). The 2'-modification may be in the arabino (up) position or ribo (down) position. A preferred 2'-arabino modification is 2'-F. Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909;

RTS-0396

-21-

PATENT

5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873;
5,670,633; 5,792,747; and 5,700,920, certain of which are
commonly owned with the instant application, and each of
which is herein incorporated by reference in its entirety.

5 A further preferred modification includes Locked Nucleic
Acids (LNAs) in which the 2'-hydroxyl group is linked to the
3' or 4' carbon atom of the sugar ring thereby forming a
bicyclic sugar moiety. The linkage is preferably a methylene
(-CH₂-)_n group bridging the 2' oxygen atom and the 4' carbon
10 atom wherein n is 1 or 2. LNAs and preparation thereof are
described in WO 98/39352 and WO 99/14226.

Oligonucleotides may also include nucleobase (often
referred to in the art simply as "base") modifications or
substitutions. As used herein, "unmodified" or "natural"
15 nucleobases include the purine bases adenine (A) and guanine
(G), and the pyrimidine bases thymine (T), cytosine (C) and
uracil (U). Modified nucleobases include other synthetic and
natural nucleobases such as 5-methylcytosine (5-me-C), 5-
hydroxymethyl cytosine, xanthine, hypoxanthine, 2-
20 aminoadenine, 6-methyl and other alkyl derivatives of adenine
and guanine, 2-propyl and other alkyl derivatives of adenine
and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine,
5-halouracil and cytosine, 5-propynyl (-C≡C-CH₃) uracil and
cytosine and other alkynyl derivatives of pyrimidine bases,
25 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil),
4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-
hydroxyl and other 8-substituted adenines and guanines, 5-
halo particularly 5-bromo, 5-trifluoromethyl and other 5-
substituted uracils and cytosines, 7-methylguanine and 7-
30 methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and
8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-
deazaguanine and 3-deazaadenine. Further modified
nucleobases include tricyclic pyrimidines such as phenoxazine

RTS-0396

-22-

PATENT

cytidine(1H-pyrimido[5,4-b][1,4]benzoxazin-2(3H)-one),
phenothiazine cytidine (1H-pyrimido[5,4-b][1,4]benzothiazin-
2(3H)-one), G-clamps such as a substituted phenoxazine
cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido[5,4-
5 b][1,4]benzoxazin-2(3H)-one), carbazole cytidine (2H-
pyrimido[4,5-b]indol-2-one), pyridoindole cytidine (H-
pyrido[3',2':4,5]pyrrolo[2,3-d]pyrimidin-2-one). Modified
nucleobases may also include those in which the purine or
pyrimidine base is replaced with other heterocycles, for
10 example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine
and 2-pyridone. Further nucleobases include those disclosed
in United States Patent No. 3,687,808, those disclosed in *The
Concise Encyclopedia Of Polymer Science And Engineering*,
pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, **1990**,
15 those disclosed by Englisch et al., *Angewandte Chemie*,
International Edition, **1991**, 30, 613, and those disclosed by
Sanghvi, Y.S., Chapter 15, *Antisense Research and
Applications*, pages 289-302, Crooke, S.T. and Lebleu, B. ,
ed., CRC Press, **1993**. Certain of these nucleobases are
20 particularly useful for increasing the binding affinity of
the oligomeric compounds of the invention. These include 5-
substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-
6 substituted purines, including 2-aminopropyladenine, 5-
propynyluracil and 5-propynylcytosine. 5-methylcytosine
25 substitutions have been shown to increase nucleic acid duplex
stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and
Lebleu, B., eds., *Antisense Research and Applications*, CRC
Press, Boca Raton, **1993**, pp. 276-278) and are presently
preferred base substitutions, even more particularly when
30 combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the
preparation of certain of the above noted modified
nucleobases as well as other modified nucleobases include,

RTS-0396

-23-

PATENT

but are not limited to, the above noted U.S. 3,687,808, as well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; 5,645,985; 5,830,653; 5,763,588; 6,005,096; and 5,681,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference, and United States patent 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. The compounds of the invention can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Typical conjugate groups include cholesterol, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties, in the context of this invention, include groups that improve oligomer uptake, enhance oligomer resistance to degradation, and/or strengthen sequence-specific hybridization with RNA. Groups that enhance the pharmacokinetic properties, in the context of this invention, include groups that improve oligomer uptake, distribution, metabolism or excretion. Representative conjugate groups are disclosed in International Patent

RTS-0396

-24-

PATENT

Application PCT/US92/09196, filed October 23, 1992 the entire disclosure of which is incorporated herein by reference. Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al.,
5 *Proc. Natl. Acad. Sci. USA*, **1989**, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1994**, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, **1992**, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, **1993**, 3, 2765-2770), a
10 thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, **1992**, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, **1991**, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, **1990**, 259, 327-330; Svinarchuk et al., *Biochimie*, **1993**, 75, 49-54), a
15 phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, **1995**, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, **1990**, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al.,
20 *Nucleosides & Nucleotides*, **1995**, 14, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, **1995**, 36, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, **1995**, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., *J.*
25 *Pharmacol. Exp. Ther.*, **1996**, 277, 923-937). Oligonucleotides of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(+)-
pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic
30 acid, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indomethacin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic. Oligonucleotide-drug

RTS-0396

-25-

PATENT

conjugates and their preparation are described in United States Patent Application 09/334,130 (filed June 15, 1999) which is incorporated herein by reference in its entirety.

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717; 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to

RTS-0396

-26-

PATENT

confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, increased stability and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. The cleavage of RNA:RNA hybrids can, in like fashion, be accomplished through the actions of endoribonucleases, such as interferon-induced RNaseL which cleaves both cellular and viral RNA. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this

RTS-0396

-27-

PATENT

invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other
5 means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The compounds of the invention may also be admixed,
10 encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor-targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative
15 United States patents that teach the preparation of such uptake, distribution and/or absorption-assisting formulations include, but are not limited to, U.S.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932; 5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556;
20 5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633; 5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854; 5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948; 5,580,575; and 5,595,756, each of which is herein incorporated by reference.

25 The antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite
30 or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.

RTS-0396

-28-

PATENT

The term "prodrug" indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/or conditions. In particular, prodrug versions of the oligonucleotides of the invention are prepared as SATE [(S-acetyl-2-thioethyl) phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published December 9, 1993 or in WO 94/26764 and U.S. 5,770,713 to Imbach et al.

The term "pharmaceutically acceptable salts" refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.

Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, **1977**, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free

RTS-0396

-29-

PATENT

acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylemaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid; and with amino acids, such as the 20 alpha-amino acids involved in the synthesis of proteins in nature, for example glutamic acid or aspartic acid, and also with phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic acid, benzenesulfonic acid, 4-methylbenzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 2- or 3-phosphoglycerate, glucose-6-phosphate, N-cyclohexylsulfamic acid (with the formation of cyclamates), or with other acid organic compounds, such as ascorbic acid. Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation. Suitable pharmaceutically acceptable cations are well known to those

RTS-0396

-30-

PATENT

skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of

5 pharmaceutically acceptable salts include but are not limited to (a) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (b) acid addition salts formed with

10 inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (c) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid,

15 palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (d) salts formed from elemental anions such as chlorine, bromine, and iodine.

20 The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of resistin

25 is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the

30 antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

The antisense compounds of the invention are useful for

RTS-0396

-31-

PATENT

research and diagnostics, because these compounds hybridize to nucleic acids encoding resistin, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense oligonucleotides of the invention with a nucleic acid encoding resistin can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits using such detection means for detecting the level of resistin in a sample may also be prepared.

The present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-O-methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be

RTS-0396

-32-

PATENT

necessary or desirable. Coated condoms, gloves and the like may also be useful. Preferred topical formulations include those in which the oligonucleotides of the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants. Preferred lipids and liposomes include neutral (e.g. dioleoylphosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearoylphosphatidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoyltetramethylaminopropyl DOTAP and dioleoylphosphatidyl ethanolamine DOTMA). Oligonucleotides of the invention may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes. Alternatively, oligonucleotides may be complexed to lipids, in particular to cationic lipids. Preferred fatty acids and esters include but are not limited arachidonic acid, oleic acid, eicosanoic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a C₁₋₁₀ alkyl ester (e.g. isopropylmyristate IPM), monoglyceride, diglyceride or pharmaceutically acceptable salt thereof. Topical formulations are described in detail in United States patent application 09/315,298 filed on May 20, 1999 which is incorporated herein by reference in its entirety.

Compositions and formulations for oral administration include powders or granules, microparticulates, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitables. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

RTS-0396

-33-

PATENT

Preferred oral formulations are those in which oligonucleotides of the invention are administered in conjunction with one or more penetration enhancers surfactants and chelators. Preferred surfactants include

5 fatty acids and/or esters or salts thereof, bile acids and/or salts thereof. Preferred bile acids/salts include chenodeoxycholic acid (CDCA) and ursodeoxychenodeoxycholic acid (UDCA), cholic acid, dehydrocholic acid, deoxycholic acid, glucolic acid, glycholic acid, glycodeoxycholic acid,

10 taurocholic acid, taurodeoxycholic acid, sodium tauro-24,25-dihydro-fusidate and sodium glycodihydrofusidate. Preferred fatty acids include arachidonic acid, undecanoic acid, oleic acid, lauric acid, caprylic acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid,

15 dicaprate, tricaprate, monoolein, dilaurin, glyceryl 1-monocaprate, 1-dodecylazacycloheptan-2-one, an acylcarnitine, an acylcholine, or a monoglyceride, a diglyceride or a pharmaceutically acceptable salt thereof (e.g. sodium). Also preferred are combinations of penetration enhancers, for

20 example, fatty acids/salts in combination with bile acids/salts. A particularly preferred combination is the sodium salt of lauric acid, capric acid and UDCA. Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxyethylene-20-cetyl ether. Oligonucleotides of the

25 invention may be delivered orally, in granular form including sprayed dried particles, or complexed to form micro or nanoparticles. Oligonucleotide complexing agents include poly-amino acids; polyimines; polyacrylates; polyalkylacrylates, polyoxethanes, polyalkylcyanoacrylates;

30 cationized gelatins, albumins, starches, acrylates, polyethyleneglycols (PEG) and starches; polyalkylcyanoacrylates; DEAE-derivatized polyimines, pollulans, celluloses and starches. Particularly preferred

RTS-0396

-34-

PATENT

complexing agents include chitosan, N-trimethylchitosan, poly-L-lysine, polyhistidine, polyornithine, polyspermines, protamine, polyvinylpyridine, polythiodiethylamino-methylethylene P(TDAE), polyaminostyrene (e.g. p-amino),
5 poly(methylcyanoacrylate), poly(ethylcyanoacrylate), poly(butylcyanoacrylate), poly(isobutylcyanoacrylate), poly(isohexylcyanoacrylate), DEAE-methacrylate, DEAE-hexylacrylate, DEAE-acrylamide, DEAE-albumin and DEAE-dextran, polymethylacrylate, polyhexylacrylate, poly(D,L-
10 lactic acid), poly(DL-lactic-co-glycolic acid (PLGA), alginate, and polyethyleneglycol (PEG). Oral formulations for oligonucleotides and their preparation are described in detail in United States applications 08/886,829 (filed July 1, 1997), 09/108,673 (filed July 1, 1998), 09/256,515 (filed
15 February 23, 1999), 09/082,624 (filed May 21, 1998) and 09/315,298 (filed May 20, 1999), each of which is incorporated herein by reference in their entirety.

Compositions and formulations for parenteral, intrathecal or intraventricular administration may include
20 sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

Pharmaceutical compositions of the present invention
25 include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

30 The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques

RTS-0396

-35-

PATENT

include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention the pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

Emulsions

The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in

RTS-0396

-36-

PATENT

diameter (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y.; Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 301).

Emulsions are often biphasic systems comprising two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be of either the water-in-oil (w/o) or the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase, the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase, the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases, and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a system of oil droplets enclosed

RTS-0396

-37-

PATENT

in globules of water stabilized in an oily continuous phase provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in

RTS-0396

-38-

PATENT

Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants, hydrophilic colloids, preservatives and antioxidants (Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell

RTS-0396

-39-

PATENT

in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

5 Since emulsions often contain a number of ingredients such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include
10 methyl paraben, propyl paraben, quaternary ammonium salts, benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as
15 tocopherols, alkyl gallates, butylated hydroxyanisole, butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

 The application of emulsion formulations via
20 dermatological, oral and parenteral routes and methods for their manufacture have been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery
25 have been very widely used because of ease of formulation, as well as efficacy from an absorption and bioavailability standpoint (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in
30 *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins

RTS-0396

-40-

PATENT

and high fat nutritive preparations are among the materials that have commonly been administered orally as o/w emulsions.

In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single optically isotropic and thermodynamically stable liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system.

Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: *Controlled Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., **1989**, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, **1985**, p. 271).

The phenomenological approach utilizing phase diagrams has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in *Pharmaceutical Dosage Forms*,

RTS-0396

-41-

PATENT

Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DA0750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated

RTS-0396

-42-

PATENT

polyglycolized C8-C10 glycerides, vegetable oils and silicone oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs, including peptides (Constantinides *et al.*, *Pharmaceutical Research*, **1994**, 11, 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, **1993**, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides *et al.*, *Pharmaceutical Research*, **1994**, 11, 1385; Ho *et al.*, *J. Pharm. Sci.*, **1996**, 85, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also been effective in the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers

RTS-0396

-43-

PATENT

to improve the properties of the formulation and to enhance the absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as
5 belonging to one of five broad categories - surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p. 92). Each of these classes has been discussed above.

10

Liposomes

There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles,
15 bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids
20 arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the
25 advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently with the cell wall, are taken up by macrophages *in vivo*.

In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a
30 diameter less than 50 nm, under the influence of a suitable transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

RTS-0396

-44-

PATENT

Further advantages of liposomes include; liposomes obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), **1988**, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes and as the merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target, and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been

RTS-0396

-45-

PATENT

administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., *Biochem. Biophys. Res. Commun.*, **1987**, 147, 980-985).

Liposomes which are pH-sensitive or negatively-charged, entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., *Journal of Controlled Release*, **1992**, 19, 269-274).

One major type of liposomal composition includes phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

RTS-0396

-46-

PATENT

Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of
5 interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner et al., *Journal of Drug Targeting*, **1992**, 2, 405-410). Further, an additional study tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon
10 using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis et al., *Antiviral Research*, **1992**, 18, 259-265).

Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin,
15 in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to
20 deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A into different layers of the skin (Hu et al. *S.T.P. Pharma. Sci.*, **1994**, 4, 6, 466).

25 Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized
30 lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G_{M1}, or (B) is derivatized with one or

RTS-0396

-47-

PATENT

more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen *et al.*, *FEBS Letters*, **1987**, 223, 42; Wu *et al.*, *Cancer Research*, **1993**, 53, 3765).

Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos *et al.* (*Ann. N.Y. Acad. Sci.*, **1987**, 507, 64) reported the ability of monosialoganglioside G_{M1}, galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon *et al.* (*Proc. Natl. Acad. Sci. U.S.A.*, **1988**, 85, 6949). U.S. Patent No. 4,837,028 and WO 88/04924, both to Allen *et al.*, disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G_{M1} or a galactocerebroside sulfate ester. U.S. Patent No. 5,543,152 (Webb *et al.*) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim *et al.*).

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto *et al.* (*Bull. Chem. Soc. Jpn.*, **1980**, 53, 2778) described liposomes comprising a nonionic detergent, 2C₁₂15G, that contains a PEG moiety. Illum *et al.* (*FEBS Lett.*, **1984**, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives. Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are

RTS-0396

-48-

PATENT

described by Sears (U.S. Patent Nos. 4,426,330 and 4,534,899). Klibanov et al. (*FEBS Lett.*, **1990**, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG

5 stearate have significant increases in blood circulation half-lives. Blume et al. (*Biochimica et Biophysica Acta*, **1990**, 1029, 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and

10 PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U.S.

15 Patent Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Patent No. 5,225,212 (both to Martin et al.) and in WO 94/20073

20 (Zalipsky et al.) Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi et al.). U.S. Patent Nos. 5,540,935 (Miyazaki et al.) and 5,556,948 (Tagawa et al.) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

25 A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Patent No. 5,264,221 to Tagawa et al. discloses protein-bonded liposomes and asserts

30 that the contents of such liposomes may include an antisense RNA. U.S. Patent No. 5,665,710 to Rahman et al. describes certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love et al. discloses liposomes

RTS-0396

-49-

PATENT

comprising antisense oligonucleotides targeted to the raf gene.

Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition.

Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their

RTS-0396

-50-

PATENT

structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers
5 such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge
10 when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl
15 benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and the soaps.

If the surfactant molecule carries a positive charge
20 when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The quaternary ammonium salts are the most used members of this class.

25 If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

30 The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

RTS-0396

-51-

PATENT

Penetration Enhancers

In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Surfactants: In connection with the present invention, surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92); and

RTS-0396

-52-

PATENT

perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm. Pharmacol.*, **1988**, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example,

5 oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, monoolein (1-monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprate, 1-

10 dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C₁₋₁₀ alkyl esters thereof (e.g., methyl, isopropyl and t-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug*

15 *Carrier Systems*, **1991**, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, **1992**, 44, 651-654).

Bile salts: The physiological role of bile includes the

20 facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, **1996**, pp. 934-935).

Various natural bile salts, and their synthetic derivatives,

25 act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate),

30 dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycocholate), glycodeoxycholic acid (sodium glycodeoxycholate), taurocholic acid (sodium

RTS-0396

-53-

PATENT

taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA, **1990**, pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33; Yamamoto et al., *J. Pharm. Exp. Ther.*, **1992**, 263, 25; Yamashita et al., *J. Pharm. Sci.*, **1990**, 79, 579-583).

Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, **1993**, 618, 315-339). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33; Buur et al., *J. Control Rel.*, **1990**, 14, 43-51).

RTS-0396

-54-

PATENT

Non-chelating non-surfactants: As used herein, non-chelating non-surfactant penetration enhancing compounds can be defined as compounds that demonstrate insignificant activity as chelating agents or as surfactants but that nonetheless enhance absorption of oligonucleotides through the alimentary mucosa (Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, **1990**, 7, 1-33). This class of penetration enhancers include, for example, unsaturated cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone derivatives (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, **1991**, page 92); and non-steroidal anti-inflammatory agents such as diclofenac sodium, indomethacin and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*, **1987**, 39, 621-626).

Agents that enhance uptake of oligonucleotides at the cellular level may also be added to the pharmaceutical and other compositions of the present invention. For example, cationic lipids, such as lipofectin (Junichi et al, U.S. Patent No. 5,705,188), cationic glycerol derivatives, and polycationic molecules, such as polylysine (Lollo et al., PCT Application WO 97/30731), are also known to enhance the cellular uptake of oligonucleotides.

Other agents may be utilized to enhance the penetration of the administered nucleic acids, including glycols such as ethylene glycol and propylene glycol, pyrrols such as 2-pyrrol, azones, and terpenes such as limonene and menthone.

Carriers

Certain compositions of the present invention also incorporate carrier compounds in the formulation. As used herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (i.e., does

RTS-0396

-55-

PATENT

not possess biological activity *per se*) but is recognized as a nucleic acid by *in vivo* processes that reduce the bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid (Miyao *et al.*, *Antisense Res. Dev.*, **1995**, 5, 115-121; Takakura *et al.*, *Antisense & Nucl. Acid Drug Dev.*, **1996**, 6, 177-183).

20 Excipients

In contrast to a carrier compound, a "pharmaceutical carrier" or "excipient" is a pharmaceutically acceptable solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc., when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (e.g., pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin,

RTS-0396

-56-

PATENT

gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g., magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention. Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include, but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

RTS-0396

-57-

PATENT

Other Components

The compositions of the present invention may additionally contain other adjunct components conventionally found in pharmaceutical compositions, at their art-established usage levels. Thus, for example, the compositions may contain additional, compatible, pharmaceutically-active materials such as, for example, antipruritics, astringents, local anesthetics or anti-inflammatory agents, or may contain additional materials useful in physically formulating various dosage forms of the compositions of the present invention, such as dyes, flavoring agents, preservatives, antioxidants, opacifiers, thickening agents and stabilizers. However, such materials, when added, should not unduly interfere with the biological activities of the components of the compositions of the present invention. The formulations can be sterilized and, if desired, mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, colorings, flavorings and/or aromatic substances and the like which do not deleteriously interact with the nucleic acid(s) of the formulation.

Aqueous suspensions may contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

Certain embodiments of the invention provide pharmaceutical compositions containing (a) one or more antisense compounds and (b) one or more other chemotherapeutic agents which function by a non-antisense mechanism. Examples of such chemotherapeutic agents include but are not limited to daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin,

RTS-0396

-58-

PATENT

esorubicin, bleomycin, mafosfamide, ifosfamide, cytosine arabinoside, bis-chloroethylnitrosurea, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamethylmelamine, pentamethylmelamine, mitoxantrone, amsacrine, chlorambucil, methylcyclohexylnitrosurea, nitrogen mustards, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-azacytidine, hydroxyurea, deoxycoformycin, 4-hydroxyperoxycyclophosphoramidate, 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUdR), methotrexate (MTX), colchicine, taxol, vincristine, vinblastine, etoposide (VP-16), trimetrexate, irinotecan, topotecan, gemcitabine, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed. 1987, pp. 1206-1228, Berkow et al., eds., Rahway, N.J. When used with the compounds of the invention, such chemotherapeutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination with one or more other such chemotherapeutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used together or sequentially.

RTS-0396

-59-

PATENT

In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC_{50} s found to be effective in *in vitro* and *in vivo* animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

While the present invention has been described with

RTS-0396**-60-****PATENT**

specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

RTS-0396

-61-

PATENT

EXAMPLES**Example 1****5 Nucleoside Phosphoramidites for Oligonucleotide Synthesis
Deoxy and 2'-alkoxy amidites**

2'-Deoxy and 2'-methoxy beta-cyanoethyldiisopropyl phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling VA).

10 Other 2'-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Patent 5,506,351, herein incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, optimized synthesis cycles were developed that incorporate multiple steps coupling longer
15 wait times relative to standard synthesis cycles.

The following abbreviations are used in the text: thin layer chromatography (TLC), melting point (MP), high pressure liquid chromatography (HPLC), Nuclear Magnetic Resonance (NMR), argon (Ar), methanol (MeOH), dichloromethane (CH₂Cl₂),
20 triethylamine (TEA), dimethyl formamide (DMF), ethyl acetate (EtOAc), dimethyl sulfoxide (DMSO), tetrahydrofuran (THF).

Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-dC) nucleotides were synthesized according to published methods (Sanghvi, et. al., *Nucleic Acids Research*, **1993**, 21,
25 3197-3203) using commercially available phosphoramidites (Glen Research, Sterling VA or ChemGenes, Needham MA) or prepared as follows:

**Preparation of 5'-O-Dimethoxytrityl-thymidine intermediate
30 for 5-methyl dC amidite**

To a 50 L glass reactor equipped with air stirrer and Ar gas line was added thymidine (1.00 kg, 4.13 mol) in anhydrous pyridine (6 L) at ambient temperature. Dimethoxytrityl (DMT)

RTS-0396

-62-

PATENT

chloride (1.47 kg, 4.34 mol, 1.05 eq) was added as a solid in four portions over 1 h. After 30 min, TLC indicated approx. 95% product, 2% thymidine, 5% DMT reagent and by-products and 2 % 3',5'-bis DMT product (R_f in EtOAc 0.45, 0.05, 0.98, 0.95 respectively). Saturated sodium bicarbonate (4 L) and CH_2Cl_2 were added with stirring (pH of the aqueous layer 7.5). An additional 18 L of water was added, the mixture was stirred, the phases were separated, and the organic layer was transferred to a second 50 L vessel. The aqueous layer was extracted with additional CH_2Cl_2 (2 x 2 L). The combined organic layer was washed with water (10 L) and then concentrated in a rotary evaporator to approx. 3.6 kg total weight. This was redissolved in CH_2Cl_2 (3.5 L), added to the reactor followed by water (6 L) and hexanes (13 L). The mixture was vigorously stirred and seeded to give a fine white suspended solid starting at the interface. After stirring for 1 h, the suspension was removed by suction through a 1/2" diameter teflon tube into a 20 L suction flask, poured onto a 25 cm Coors Buchner funnel, washed with water (2 x 3 L) and a mixture of hexanes- CH_2Cl_2 (4:1, 2x3 L) and allowed to air dry overnight in pans (1" deep). This was further dried in a vacuum oven (75°C, 0.1 mm Hg, 48 h) to a constant weight of 2072 g (93%) of a white solid, (mp 122-124°C). TLC indicated a trace contamination of the bis DMT product. NMR spectroscopy also indicated that 1-2 mole percent pyridine and about 5 mole percent of hexanes was still present.

Preparation of 5'-O-Dimethoxytrityl-2'-deoxy-5-methylcytidine intermediate for 5-methyl-dC amidite

To a 50 L Schott glass-lined steel reactor equipped with an electric stirrer, reagent addition pump (connected to an addition funnel), heating/cooling system, internal

RTS-0396

-63-

PATENT

thermometer and an Ar gas line was added 5'-O-dimethoxytrityl-thymidine (3.00 kg, 5.51 mol), anhydrous acetonitrile (25 L) and TEA (12.3 L, 88.4 mol, 16 eq). The mixture was chilled with stirring to -10°C internal temperature (external -20°C). Trimethylsilylchloride (2.1 L, 16.5 mol, 3.0 eq) was added over 30 minutes while maintaining the internal temperature below -5°C, followed by a wash of anhydrous acetonitrile (1 L). Note: the reaction is mildly exothermic and copious hydrochloric acid fumes form over the course of the addition. The reaction was allowed to warm to 0°C and the reaction progress was confirmed by TLC (EtOAc-hexanes 4:1; R_f 0.43 to 0.84 of starting material and silyl product, respectively). Upon completion, triazole (3.05 kg, 44 mol, 8.0 eq) was added the reaction was cooled to -20°C internal temperature (external -30°C). Phosphorous oxychloride (1035 mL, 11.1 mol, 2.01 eq) was added over 60 min so as to maintain the temperature between -20°C and -10°C during the strongly exothermic process, followed by a wash of anhydrous acetonitrile (1 L). The reaction was warmed to 0°C and stirred for 1 h. TLC indicated a complete conversion to the triazole product (R_f 0.83 to 0.34 with the product spot glowing in long wavelength UV light). The reaction mixture was a peach-colored thick suspension, which turned darker red upon warming without apparent decomposition. The reaction was cooled to -15°C internal temperature and water (5 L) was slowly added at a rate to maintain the temperature below +10°C in order to quench the reaction and to form a homogenous solution. (Caution: this reaction is initially very strongly exothermic). Approximately one-half of the reaction volume (22 L) was transferred by air pump to another vessel, diluted with EtOAc (12 L) and extracted with water (2 x 8 L). The combined water layers were back-extracted with EtOAc (6 L). The water layer was discarded and the organic

RTS-0396

-64-

PATENT

layers were concentrated in a 20 L rotary evaporator to an oily foam. The foam was coevaporated with anhydrous acetonitrile (4 L) to remove EtOAc. (note: dioxane may be used instead of anhydrous acetonitrile if dried to a hard foam). The second half of the reaction was treated in the same way. Each residue was dissolved in dioxane (3 L) and concentrated ammonium hydroxide (750 mL) was added. A homogenous solution formed in a few minutes and the reaction was allowed to stand overnight (although the reaction is complete within 1 h).

TLC indicated a complete reaction (product R_f 0.35 in EtOAc-MeOH 4:1). The reaction solution was concentrated on a rotary evaporator to a dense foam. Each foam was slowly redissolved in warm EtOAc (4 L; 50°C), combined in a 50 L glass reactor vessel, and extracted with water (2 x 4L) to remove the triazole by-product. The water was back-extracted with EtOAc (2 L). The organic layers were combined and concentrated to about 8 kg total weight, cooled to 0°C and seeded with crystalline product. After 24 hours, the first crop was collected on a 25 cm Coors Buchner funnel and washed repeatedly with EtOAc (3 x 3L) until a white powder was left and then washed with ethyl ether (2 x 3L). The solid was put in pans (1" deep) and allowed to air dry overnight. The filtrate was concentrated to an oil, then redissolved in EtOAc (2 L), cooled and seeded as before. The second crop was collected and washed as before (with proportional solvents) and the filtrate was first extracted with water (2 x 1L) and then concentrated to an oil. The residue was dissolved in EtOAc (1 L) and yielded a third crop which was treated as above except that more washing was required to remove a yellow oily layer.

After air-drying, the three crops were dried in a vacuum oven (50°C, 0.1 mm Hg, 24 h) to a constant weight (1750, 600

RTS-0396

-65-

PATENT

and 200 g, respectively) and combined to afford 2550 g (85%) of a white crystalline product (MP 215-217°C) when TLC and NMR spectroscopy indicated purity. The mother liquor still contained mostly product (as determined by TLC) and a small amount of triazole (as determined by NMR spectroscopy), bis DMT product and unidentified minor impurities. If desired, the mother liquor can be purified by silica gel chromatography using a gradient of MeOH (0-25%) in EtOAc to further increase the yield.

10

Preparation of 5'-O-Dimethoxytrityl-2'-deoxy-N⁴-benzoyl-5-methylcytidine penultimate intermediate for 5-methyl dC amidite

Crystalline 5'-O-dimethoxytrityl-5-methyl-2'-deoxycytidine (2000 g, 3.68 mol) was dissolved in anhydrous DMF (6.0 kg) at ambient temperature in a 50 L glass reactor vessel equipped with an air stirrer and argon line. Benzoic anhydride (Chem Impex not Aldrich, 874 g, 3.86 mol, 1.05 eq) was added and the reaction was stirred at ambient temperature for 8 h. TLC (CH₂Cl₂-EtOAc; CH₂Cl₂-EtOAc 4:1; R_f 0.25) indicated approx. 92% complete reaction. An additional amount of benzoic anhydride (44 g, 0.19 mol) was added. After a total of 18 h, TLC indicated approx. 96% reaction completion. The solution was diluted with EtOAc (20 L), TEA (1020 mL, 7.36 mol, ca 2.0 eq) was added with stirring, and the mixture was extracted with water (15 L, then 2 x 10 L). The aqueous layer was removed (no back-extraction was needed) and the organic layer was concentrated in 2 x 20 L rotary evaporator flasks until a foam began to form. The residues were coevaporated with acetonitrile (1.5 L each) and dried (0.1 mm Hg, 25°C, 24 h) to 2520 g of a dense foam. High pressure liquid chromatography (HPLC) revealed a

RTS-0396

-66-

PATENT

contamination of 6.3% of N⁴, 3'-O-dibenzoyl product, but very little other impurities.

The product was purified by Biotage column chromatography (5 kg Biotage) prepared with 65:35:1 hexanes-EtOAc-TEA (4L). The crude product (800 g), dissolved in CH₂Cl₂ (2 L), was applied to the column. The column was washed with the 65:35:1 solvent mixture (20 kg), then 20:80:1 solvent mixture (10 kg), then 99:1 EtOAc:TEA (17kg). The fractions containing the product were collected, and any fractions containing the product and impurities were retained to be resubjected to column chromatography. The column was re-equilibrated with the original 65:35:1 solvent mixture (17 kg). A second batch of crude product (840 g) was applied to the column as before. The column was washed with the following solvent gradients: 65:35:1 (9 kg), 55:45:1 (20 kg), 20:80:1 (10 kg), and 99:1 EtOAc:TEA (15 kg). The column was reequilibrated as above, and a third batch of the crude product (850 g) plus impure fractions recycled from the two previous columns (28 g) was purified following the procedure for the second batch. The fractions containing pure product combined and concentrated on a 20L rotary evaporator, co-evaporated with acetone (3 L) and dried (0.1 mm Hg, 48 h, 25°C) to a constant weight of 2023 g (85%) of white foam and 20 g of slightly contaminated product from the third run. HPLC indicated a purity of 99.8% with the balance as the diBenzoyl product.

[5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-deoxy-N⁴-benzoyl-5-methylcytidin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (5-methyl dC amidite)

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-deoxy-N⁴-benzoyl-5-methylcytidine (998 g, 1.5 mol) was dissolved in anhydrous DMF (2 L). The solution was co-evaporated with toluene (300

RTS-0396

-67-

PATENT

ml) at 50°C under reduced pressure, then cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (680 g, 2.26 mol) and tetrazole (52.5 g, 0.75 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (15 ml) was added and the mixture was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (2.5 L) and water (600 ml), and extracted with hexane (3 x 3 L). The mixture was diluted with water (1.2 L) and extracted with a mixture of toluene (7.5 L) and hexane (6 L). The two layers were separated, the upper layer was washed with DMF-water (7:3 v/v, 3 x 2 L) and water (3 x 2 L), and the phases were separated. The organic layer was dried (Na₂SO₄), filtered and rotary evaporated. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried to a constant weight (25 °C, 0.1mm Hg, 40 h) to afford 1250 g an off-white foam solid (96%).

2'-Fluoro amidites

2'-Fluorodeoxyadenosine amidites

2'-fluoro oligonucleotides were synthesized as described previously [Kawasaki, et. al., *J. Med. Chem.*, **1993**, 36, 831-841] and United States patent 5,670,633, herein incorporated by reference. The preparation of 2'-fluoropyrimidines containing a 5-methyl substitution are described in US Patent 5,861,493. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as starting material and whereby the 2'-alpha-fluoro atom is introduced by a S_N2-displacement of a 2'-beta-triflate group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP) intermediate. Deprotection of the

RTS-0396

-68-

PATENT

THP and N6-benzoyl groups was accomplished using standard methodologies to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

5 **2'-Fluorodeoxyguanosine**

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and conversion to the intermediate isobutyryl-
10 arabinofuranosylguanosine. Alternatively, isobutyryl-arabinofuranosylguanosine was prepared as described by Ross et al., (Nucleosides & Nucleosides, 16, 1645, 1997). Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give isobutyryl di-THP
15 protected arabinofuranosylguanine. Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

20

2'-Fluorouridine

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70%
25 hydrogen fluoride-pyridine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-Fluorodeoxycytidine

2'-deoxy-2'-fluorocytidine was synthesized via amination
30 of 2'-deoxy-2'-fluorouridine, followed by selective protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

RTS-0396

-69-

PATENT

2'-O-(2-Methoxyethyl) modified amidites

2'-O-Methoxyethyl-substituted nucleoside amidites (otherwise known as MOE amidites) are prepared as follows, or alternatively, as per the methods of Martin, P., (Helvetica Chimica Acta, **1995**, 78, 486-504).

Preparation of 2'-O-(2-methoxyethyl)-5-methyluridine intermediate

10 2,2'-Anhydro-5-methyl-uridine (2000 g, 8.32 mol), tris(2-methoxyethyl)borate (2504 g, 10.60 mol), sodium bicarbonate (60 g, 0.70 mol) and anhydrous 2-methoxyethanol (5 L) were combined in a 12 L three necked flask and heated to 130 °C (internal temp) at atmospheric pressure, under an argon atmosphere with stirring for 21 h. TLC indicated a complete reaction. The solvent was removed under reduced pressure until a sticky gum formed (50-85°C bath temp and 100-11 mm Hg) and the residue was redissolved in water (3 L) and heated to boiling for 30 min in order to hydrolyze the borate esters. The water was removed under reduced pressure until a foam began to form and then the process was repeated. HPLC indicated about 77% product, 15% dimer (5' of product attached to 2' of starting material) and unknown derivatives, and the balance was a single unresolved early eluting peak.

25 The gum was redissolved in brine (3 L), and the flask was rinsed with additional brine (3 L). The combined aqueous solutions were extracted with chloroform (20 L) in a heavier-than continuous extractor for 70 h. The chloroform layer was concentrated by rotary evaporation in a 20 L flask to a sticky foam (2400 g). This was coevaporated with MeOH (400 mL) and EtOAc (8 L) at 75°C and 0.65 atm until the foam dissolved at which point the vacuum was lowered to about 0.5 atm. After 2.5 L of distillate was collected a precipitate

RTS-0396

-70-

PATENT

began to form and the flask was removed from the rotary evaporator and stirred until the suspension reached ambient temperature. EtOAc (2 L) was added and the slurry was filtered on a 25 cm table top Buchner funnel and the product was washed with EtOAc (3 x 2 L). The bright white solid was air dried in pans for 24 h then further dried in a vacuum oven (50°C, 0.1 mm Hg, 24 h) to afford 1649 g of a white crystalline solid (mp 115.5-116.5°C).

The brine layer in the 20 L continuous extractor was further extracted for 72 h with recycled chloroform. The chloroform was concentrated to 120 g of oil and this was combined with the mother liquor from the above filtration (225 g), dissolved in brine (250 mL) and extracted once with chloroform (250 mL). The brine solution was continuously extracted and the product was crystallized as described above to afford an additional 178 g of crystalline product containing about 2% of thymine. The combined yield was 1827 g (69.4%). HPLC indicated about 99.5% purity with the balance being the dimer.

Preparation of 5'-O-DMT-2'-O-(2-methoxyethyl)-5-methyluridine penultimate intermediate

In a 50 L glass-lined steel reactor, 2'-O-(2-methoxyethyl)-5-methyl-uridine (MOE-T, 1500 g, 4.738 mol), lutidine (1015 g, 9.476 mol) were dissolved in anhydrous acetonitrile (15 L). The solution was stirred rapidly and chilled to -10°C (internal temperature). Dimethoxytriphenylmethyl chloride (1765.7 g, 5.21 mol) was added as a solid in one portion. The reaction was allowed to warm to -2°C over 1 h. (Note: The reaction was monitored closely by TLC (EtOAc) to determine when to stop the reaction so as to not generate the undesired bis-DMT substituted side product). The reaction was allowed to warm from -2 to 3°C

RTS-0396

-71-

PATENT

over 25 min. then quenched by adding MeOH (300 mL) followed after 10 min by toluene (16 L) and water (16 L). The solution was transferred to a clear 50 L vessel with a bottom outlet, vigorously stirred for 1 minute, and the layers
5 separated. The aqueous layer was removed and the organic layer was washed successively with 10% aqueous citric acid (8 L) and water (12 L). The product was then extracted into the aqueous phase by washing the toluene solution with aqueous sodium hydroxide (0.5N, 16 L and 8 L). The combined aqueous
10 layer was overlaid with toluene (12 L) and solid citric acid (8 moles, 1270 g) was added with vigorous stirring to lower the pH of the aqueous layer to 5.5 and extract the product into the toluene. The organic layer was washed with water (10 L) and TLC of the organic layer indicated a trace of DMT-
15 O-Me, bis DMT and dimer DMT.

The toluene solution was applied to a silica gel column (6 L sintered glass funnel containing approx. 2 kg of silica gel slurried with toluene (2 L) and TEA(25 mL)) and the fractions were eluted with toluene (12 L) and EtOAc (3 x 4 L)
20 using vacuum applied to a filter flask placed below the column. The first EtOAc fraction containing both the desired product and impurities were resubjected to column chromatography as above. The clean fractions were combined, rotary evaporated to a foam, coevaporated with acetonitrile
25 (6 L) and dried in a vacuum oven (0.1 mm Hg, 40 h, 40°C) to afford 2850 g of a white crisp foam. NMR spectroscopy indicated a 0.25 mole % remainder of acetonitrile (calculates to be approx. 47 g) to give a true dry weight of 2803 g (96%). HPLC indicated that the product was 99.41% pure, with
30 the remainder being 0.06 DMT-O-Me, 0.10 unknown, 0.44 bis DMT, and no detectable dimer DMT or 3'-O-DMT.

RTS-0396

-72-

PATENT

Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-5-methyluridin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE T amidite)

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-5-methyluridine (1237 g, 2.0 mol) was dissolved in anhydrous DMF (2.5 L). The solution was co-evaporated with toluene (200 ml) at 50°C under reduced pressure, then cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (900 g, 3.0 mol) and tetrazole (70 g, 1.0 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (20 ml) was added and the solution was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (3.5 L) and water (600 ml) and extracted with hexane (3 x 3L). The mixture was diluted with water (1.6 L) and extracted with the mixture of toluene (12 L) and hexanes (9 L). The upper layer was washed with DMF-water (7:3 v/v, 3x3 L) and water (3x3 L). The organic layer was dried (Na₂SO₄), filtered and evaporated. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried in a vacuum oven (25°C, 0.1mm Hg, 40 h) to afford 1526 g of an off-white foamy solid (95%).

Preparation of 5'-O-Dimethoxytrityl-2'-O-(2-methoxyethyl)-5-methylcytidine intermediate

To a 50 L Schott glass-lined steel reactor equipped with an electric stirrer, reagent addition pump (connected to an addition funnel), heating/cooling system, internal thermometer and argon gas line was added 5'-O-dimethoxytrityl-2'-O-(2-methoxyethyl)-5-methyl-uridine (2.616 kg, 4.23 mol, purified by base extraction only and no scrub column), anhydrous acetonitrile (20 L), and TEA (9.5 L, 67.7 mol, 16 eq). The mixture was chilled with stirring to -10°C

RTS-0396

-73-

PATENT

internal temperature (external -20°C).

Trimethylsilylchloride (1.60 L, 12.7 mol, 3.0 eq) was added over 30 min. while maintaining the internal temperature below -5°C, followed by a wash of anhydrous acetonitrile (1 L).

- 5 (Note: the reaction is mildly exothermic and copious hydrochloric acid fumes form over the course of the addition). The reaction was allowed to warm to 0°C and the reaction progress was confirmed by TLC (EtOAc, R_f 0.68 and 0.87 for starting material and silyl product, respectively).
- 10 Upon completion, triazole (2.34 kg, 33.8 mol, 8.0 eq) was added the reaction was cooled to -20°C internal temperature (external -30°C). Phosphorous oxychloride (793 mL, 8.51 mol, 2.01 eq) was added slowly over 60 min so as to maintain the temperature between -20°C and -10°C (note: strongly
- 15 exothermic), followed by a wash of anhydrous acetonitrile (1 L). The reaction was warmed to 0°C and stirred for 1 h, at which point it was an off-white thick suspension. TLC indicated a complete conversion to the triazole product (EtOAc, R_f 0.87 to 0.75 with the product spot glowing in long
- 20 wavelength UV light). The reaction was cooled to -15°C and water (5 L) was slowly added at a rate to maintain the temperature below +10°C in order to quench the reaction and to form a homogenous solution. (Caution: this reaction is initially very strongly exothermic). Approximately one-half
- 25 of the reaction volume (22 L) was transferred by air pump to another vessel, diluted with EtOAc (12 L) and extracted with water (2 x 8 L). The second half of the reaction was treated in the same way. The combined aqueous layers were back-extracted with EtOAc (8 L) The organic layers were combined
- 30 and concentrated in a 20 L rotary evaporator to an oily foam. The foam was coevaporated with anhydrous acetonitrile (4 L) to remove EtOAc. (note: dioxane may be used instead of anhydrous acetonitrile if dried to a hard foam). The residue

RTS-0396

-74-

PATENT

was dissolved in dioxane (2 L) and concentrated ammonium hydroxide (750 mL) was added. A homogenous solution formed in a few minutes and the reaction was allowed to stand overnight

- 5 TLC indicated a complete reaction (CH_2Cl_2 -acetone-MeOH, 20:5:3, R_f 0.51). The reaction solution was concentrated on a rotary evaporator to a dense foam and slowly redissolved in warm CH_2Cl_2 (4 L, 40°C) and transferred to a 20 L glass extraction vessel equipped with a air-powered stirrer. The
- 10 organic layer was extracted with water (2 x 6 L) to remove the triazole by-product. (Note: In the first extraction an emulsion formed which took about 2 h to resolve). The water layer was back-extracted with CH_2Cl_2 (2 x 2 L), which in turn was washed with water (3 L). The combined organic layer was
- 15 concentrated in 2 x 20 L flasks to a gum and then recrystallized from EtOAc seeded with crystalline product. After sitting overnight, the first crop was collected on a 25 cm Coors Buchner funnel and washed repeatedly with EtOAc until a white free-flowing powder was left (about 3 x 3 L).
- 20 The filtrate was concentrated to an oil recrystallized from EtOAc, and collected as above. The solid was air-dried in pans for 48 h, then further dried in a vacuum oven (50°C, 0.1mm Hg, 17 h) to afford 2248 g of a bright white, dense solid (86%). An HPLC analysis indicated both crops to be
- 25 99.4% pure and NMR spectroscopy indicated only a faint trace of EtOAc remained.

Preparation of 5'-O-dimethoxytrityl-2'-O-(2-methoxyethyl)-N4-benzoyl-5-methyl-cytidine penultimate intermediate:

- 30 Crystalline 5'-O-dimethoxytrityl-2'-O-(2-methoxyethyl)-5-methyl-cytidine (1000 g, 1.62 mol) was suspended in anhydrous DMF (3 kg) at ambient temperature and stirred under an Ar atmosphere. Benzoic anhydride (439.3 g, 1.94 mol) was

RTS-0396

-75-

PATENT

added in one portion. The solution clarified after 5 hours and was stirred for 16 h. HPLC indicated 0.45% starting material remained (as well as 0.32% N⁴, 3'-O-bis Benzoyl). An additional amount of benzoic anhydride (6.0 g, 0.0265 mol) was added and after 17 h, HPLC indicated no starting material was present. TEA (450 mL, 3.24 mol) and toluene (6 L) were added with stirring for 1 minute. The solution was washed with water (4 x 4 L), and brine (2 x 4 L). The organic layer was partially evaporated on a 20 L rotary evaporator to remove 4 L of toluene and traces of water. HPLC indicated that the bis benzoyl side product was present as a 6% impurity. The residue was diluted with toluene (7 L) and anhydrous DMSO (200 mL, 2.82 mol) and sodium hydride (60% in oil, 70 g, 1.75 mol) was added in one portion with stirring at ambient temperature over 1 h. The reaction was quenched by slowly adding then washing with aqueous citric acid (10%, 100 mL over 10 min, then 2 x 4 L), followed by aqueous sodium bicarbonate (2%, 2 L), water (2 x 4 L) and brine (4 L). The organic layer was concentrated on a 20 L rotary evaporator to about 2 L total volume. The residue was purified by silica gel column chromatography (6 L Buchner funnel containing 1.5 kg of silica gel wetted with a solution of EtOAc-hexanes-TEA(70:29:1)). The product was eluted with the same solvent (30 L) followed by straight EtOAc (6 L). The fractions containing the product were combined, concentrated on a rotary evaporator to a foam and then dried in a vacuum oven (50°C, 0.2 mm Hg, 8 h) to afford 1155 g of a crisp, white foam (98%). HPLC indicated a purity of >99.7%.

30 **Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁴-benzoyl-5-methylcytidin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE 5-Me-C amidite)**

RTS-0396

-76-

PATENT

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁴-benzoyl-5-methylcytidine (1082 g, 1.5 mol) was dissolved in anhydrous DMF (2 L) and co-evaporated with toluene (300 ml) at 50 °C under reduced pressure. The mixture was cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (680 g, 2.26 mol) and tetrazole (52.5 g, 0.75 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (30 ml) was added, and the mixture was left at room temperature for 5 hours. TEA (300 ml) was added, the mixture was diluted with DMF (1 L) and water (400 ml) and extracted with hexane (3 x 3 L). The mixture was diluted with water (1.2 L) and extracted with a mixture of toluene (9 L) and hexanes (6 L). The two layers were separated and the upper layer was washed with DMF-water (60:40 v/v, 3 x 3 L) and water (3 x 2 L). The organic layer was dried (Na₂SO₄), filtered and evaporated. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried in a vacuum oven (25 °C, 0.1mm Hg, 40 h) to afford 1336 g of an off-white foam (97%).

Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁶-benzoyl-adenosine-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE A amidite)

5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁶-benzoyl-adenosine (purchased from Reliable Biopharmaceutical, St. Lois, MO), 1098 g, 1.5 mol) was dissolved in anhydrous DMF (3 L) and co-evaporated with toluene (300 ml) at 50 °C. The mixture was cooled to room temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (680 g, 2.26 mol) and tetrazole (78.8 g, 1.24 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (30 ml) was added, and mixture was left at room temperature for 5 hours. TEA (300 ml) was

RTS-0396

-77-

PATENT

added, the mixture was diluted with DMF (1 L) and water (400 ml) and extracted with hexanes (3 x 3 L). The mixture was diluted with water (1.4 L) and extracted with the mixture of toluene (9 L) and hexanes (6 L). The two layers were
5 separated and the upper layer was washed with DMF-water (60:40, v/v, 3 x 3 L) and water (3 x 2 L). The organic layer was dried (Na₂SO₄), filtered and evaporated to a sticky foam. The residue was co-evaporated with acetonitrile (2.5 L) under reduced pressure and dried in a vacuum oven (25 °C, 0.1mm Hg,
10 40 h) to afford 1350 g of an off-white foam solid (96%).

Preparation of [5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁴-isobutyrylguanosin-3'-O-yl]-2-cyanoethyl-N,N-diisopropylphosphoramidite (MOE G amidite)

15 5'-O-(4,4'-Dimethoxytriphenylmethyl)-2'-O-(2-methoxyethyl)-N⁴-isobutyrylguanosine (purchased from Reliable Biopharmaceutical, St. Louis, MO, 1426 g, 2.0 mol) was dissolved in anhydrous DMF (2 L). The solution was co-evaporated with toluene (200 ml) at 50 °C, cooled to room
20 temperature and 2-cyanoethyl tetraisopropylphosphorodiamidite (900 g, 3.0 mol) and tetrazole (68 g, 0.97 mol) were added. The mixture was shaken until all tetrazole was dissolved, N-methylimidazole (30 ml) was added, and the mixture was left at room temperature for 5 hours. TEA (300 ml) was added, the
25 mixture was diluted with DMF (2 L) and water (600 ml) and extracted with hexanes (3 x 3 L). The mixture was diluted with water (2 L) and extracted with a mixture of toluene (10 L) and hexanes (5 L). The two layers were separated and the upper layer was washed with DMF-water (60:40, v/v, 3x3 L).
30 EtOAc (4 L) was added and the solution was washed with water (3 x 4 L). The organic layer was dried (Na₂SO₄), filtered and evaporated to approx. 4 kg. Hexane (4 L) was added, the mixture was shaken for 10 min, and the supernatant liquid was

RTS-0396

-78-

PATENT

decanted. The residue was co-evaporated with acetonitrile (2 x 2 L) under reduced pressure and dried in a vacuum oven (25 °C, 0.1mm Hg, 40 h) to afford 1660 g of an off-white foamy solid (91%).

5

2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-(dimethylaminooxyethyl) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites (also known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside amidites) are prepared as described in the following paragraphs. Adenosine, cytidine and guanosine nucleoside amidites are prepared similarly to the thymidine (5-methyluridine) except the exocyclic amines are protected with a benzoyl moiety in the case of adenosine and cytidine and with isobutyryl in the case of guanosine.

15

5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine

O²-2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese, Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g, 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml) at ambient temperature under an argon atmosphere and with mechanical stirring. tert-Butyldiphenylchlorosilane (125.8g, 119.0mL, 1.1eq, 0.458mmol) was added in one portion. The reaction was stirred for 16 h at ambient temperature. TLC (R_f 0.22, EtOAc) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between CH₂Cl₂ (1 L) and saturated sodium bicarbonate (2 x 1 L) and brine (1 L). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of EtOAc and ethyl ether (600mL) and cooling the

20

25

30

RTS-0396

-79-

PATENT

solution to -10°C afforded a white crystalline solid which was collected by filtration, washed with ethyl ether (3 x2 00 mL) and dried (40°C, 1mm Hg, 24 h) to afford 149g of white solid (74.8%). TLC and NMR spectroscopy were consistent with pure
5 product.

5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine

In the fume hood, ethylene glycol (350 mL, excess) was
10 added cautiously with manual stirring to a 2 L stainless steel pressure reactor containing borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). (Caution : evolves hydrogen gas). 5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq)
15 were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160 °C was reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel was cooled to ambient temperature and opened. TLC (EtOAc, R_f 0.67 for desired product and R_f
20 0.82 for ara-T side product) indicated about 70% conversion to the product. The solution was concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol. (Alternatively, once the THF has evaporated the
25 solution can be diluted with water and the product extracted into EtOAc). The residue was purified by column chromatography (2kg silica gel, EtOAc-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, evaporated and dried to afford 84 g of a white crisp foam (50%),
30 contaminated starting material (17.4g, 12% recovery) and pure reusable starting material (20g, 13% recovery). TLC and NMR spectroscopy were consistent with 99% pure product.

RTS-0396

-80-

PATENT

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylldiphenylsilyl-5-methyluridine

5'-O-tert-Butylldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) was mixed with
5 triphenylphosphine (11.63g, 44.36mmol) and N-hydroxyphthalimide (7.24g, 44.36mmol) and dried over P₂O₅ under high vacuum for two days at 40°C. The reaction mixture was flushed with argon and dissolved in dry THF (369.8mL, Aldrich, sure seal bottle). Diethyl-azodicarboxylate
10 (6.98mL, 44.36mmol) was added dropwise to the reaction mixture with the rate of addition maintained such that the resulting deep red coloration is just discharged before adding the next drop. The reaction mixture was stirred for 4 hrs., after which time TLC (EtOAc:hexane, 60:40) indicated
15 that the reaction was complete. The solvent was evaporated in vacuo and the residue purified by flash column chromatography (eluted with 60:40 EtOAc:hexane), to yield 2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylldiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%) upon rotary
20 evaporation.

5'-O-tert-butylldiphenylsilyl-2'-O-([2-formadoximinooxy)ethyl]-5-methyluridine

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butylldiphenylsilyl-5-
25 methyluridine (3.1g, 4.5mmol) was dissolved in dry CH₂Cl₂ (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 h the mixture was filtered, the filtrate washed with ice cold CH₂Cl₂, and the combined organic phase was washed with water and brine and dried
30 (anhydrous Na₂SO₄). The solution was filtered and evaporated to afford 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). Formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting mixture

RTS-0396

-81-

PATENT

was stirred for 1 h. The solvent was removed under vacuum and the residue was purified by column chromatography to yield 5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine as white foam (1.95 g, 78%) upon
5 rotary evaporation.

**5'-O-*tert*-Butyldiphenylsilyl-2'-O-[N,N
dimethylaminooxyethyl]-5-methyluridine**

5'-O-*tert*-butyldiphenylsilyl-2'-O-[(2-
10 formadoximinooxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6mL) and cooled to 10°C under inert atmosphere. Sodium cyanoborohydride (0.39g, 6.13mmol) was added and the reaction mixture was stirred. After 10 minutes
15 the reaction was warmed to room temperature and stirred for 2 h. while the progress of the reaction was monitored by TLC (5% MeOH in CH₂Cl₂). Aqueous NaHCO₃ solution (5%, 10mL) was added and the product was extracted with EtOAc (2 x 20 mL). The organic phase was dried over anhydrous Na₂SO₄, filtered,
20 and evaporated to dryness. This entire procedure was repeated with the resulting residue, with the exception that formaldehyde (20% w/w, 30 mL, 3.37 mol) was added upon dissolution of the residue in the PPTS/MeOH solution. After the extraction and evaporation, the residue was purified by
25 flash column chromatography and (eluted with 5% MeOH in CH₂Cl₂) to afford 5'-O-*tert*-butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine as a white foam (14.6g, 80%) upon rotary evaporation.

30 **2'-O-(dimethylaminooxyethyl)-5-methyluridine**

Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and TEA (1.67mL, 12mmol, dry, stored over KOH) and added to 5'-O-*tert*-butyldiphenylsilyl-2'-O-

RTS-0396

-82-

PATENT

[N,N-dimethylaminooxyethyl]-5-methyluridine (1.40g, 2.4mmol). The reaction was stirred at room temperature for 24 hrs and monitored by TLC (5% MeOH in CH₂Cl₂). The solvent was removed under vacuum and the residue purified by flash column chromatography (eluted with 10% MeOH in CH₂Cl₂) to afford 2'-O-(dimethylaminooxyethyl)-5-methyluridine (766mg, 92.5%) upon rotary evaporation of the solvent.

5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine
2'-O-(dimethylaminooxyethyl)-5-methyluridine (750 mg, 2.17 mmol) was dried over P₂O₅ under high vacuum overnight at 40°C, co-evaporated with anhydrous pyridine (20 mL), and dissolved in pyridine (11 mL) under argon atmosphere. 4-dimethylaminopyridine (26.5 mg, 2.60 mmol) and 4,4'-dimethoxytrityl chloride (880 mg, 2.60 mmol) were added to the pyridine solution and the reaction mixture was stirred at room temperature until all of the starting material had reacted. Pyridine was removed under vacuum and the residue was purified by column chromatography (eluted with 10% MeOH in CH₂Cl₂ containing a few drops of pyridine) to yield 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%) upon rotary evaporation.

5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

5'-O-DMT-2'-O-(dimethylaminoxyethyl)-5-methyluridine (1.08 g, 1.67 mmol) was co-evaporated with toluene (20 mL), N,N-diisopropylamine tetrazonide (0.29 g, 1.67 mmol) was added and the mixture was dried over P₂O₅ under high vacuum overnight at 40°C. This was dissolved in anhydrous acetonitrile (8.4 mL) and 2-cyanoethyl-N,N,N¹,N¹-tetraisopropylphosphoramidite (2.12 mL, 6.08 mmol) was added.

RTS-0396

-83-

PATENT

The reaction mixture was stirred at ambient temperature for 4 h under inert atmosphere. The progress of the reaction was monitored by TLC (hexane:EtOAc 1:1). The solvent was evaporated, then the residue was dissolved in EtOAc (70mL) and washed with 5% aqueous NaHCO₃ (40mL). The EtOAc layer was dried over anhydrous Na₂SO₄, filtered, and concentrated. The residue obtained was purified by column chromatography (EtOAc as eluent) to afford 5'-O-DMT-2'-O-(2-N,N-dimethylaminoxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%) upon rotary evaporation.

2'-(Aminooxyethoxy) nucleoside amidites

2'-(Aminooxyethoxy) nucleoside amidites (also known in the art as 2'-O-(aminooxyethyl) nucleoside amidites) are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared similarly.

N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine riboside.

Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3'-O-isomer. 2'-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2'-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinasso, C. J., WO 94/02501 A1 940203.) Standard protection procedures should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine and

RTS-0396

-84-

PATENT

2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-hydroxyethyl)-5'-O-(4,4'-dimethoxytrityl)guanosine. As before the hydroxyl group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may be phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-([2-phthalamidoxy]ethyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite].

2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites

2'-dimethylaminoethoxyethoxy nucleoside amidites (also known in the art as 2'-O-dimethylaminoethoxyethyl, i.e., 2'-O-CH₂-O-CH₂-N(CH₂)₂, or 2'-DMAEOE nucleoside amidites) are prepared as follows. Other nucleoside amidites are prepared similarly.

2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) was slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL bomb. (Caution: Hydrogen gas evolves as the solid dissolves). O²-,2'-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) were added and the bomb was sealed, placed in an oil bath and heated to 155°C for 26 h. then cooled to room temperature. The crude solution was concentrated, the residue was diluted with water (200 mL) and extracted with hexanes (200 mL). The product was extracted from the aqueous layer with EtOAc (3 x 200 mL) and the combined organic layers were washed once with water, dried over anhydrous sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography

RTS-0396

-85-

PATENT

(eluted with 5:100:2 MeOH/CH₂Cl₂/TEA) as the eluent. The appropriate fractions were combined and evaporated to afford the product as a white solid.

5 **5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl)]-5-methyl uridine**

To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl)]-5-methyl uridine in anhydrous pyridine (8 mL), was added TEA (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 10 0.87 g, 2 eq.) and the reaction was stirred for 1 h. The reaction mixture was poured into water (200 mL) and extracted with CH₂Cl₂ (2 x 200 mL). The combined CH₂Cl₂ layers were washed with saturated NaHCO₃ solution, followed by saturated NaCl solution, dried over anhydrous sodium sulfate, filtered 15 and evaporated. The residue was purified by silica gel column chromatography (eluted with 5:100:1 MeOH/CH₂Cl₂/TEA) to afford the product.

20 **5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl)]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite**

Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) were added to a solution of 5'-O-dimethoxytrityl-2'-O-[2(2-N,N- 25 dimethylaminoethoxy)ethyl)]-5-methyluridine (2.17 g, 3 mmol) dissolved in CH₂Cl₂ (20 mL) under an atmosphere of argon. The reaction mixture was stirred overnight and the solvent evaporated. The resulting residue was purified by silica gel column chromatography with EtOAc as the eluent to afford the 30 title compound.

Example 2

Oligonucleotide synthesis

RTS-0396

-86-

PATENT

Unsubstituted and substituted phosphodiester (P=O) oligonucleotides are synthesized on an automated DNA synthesizer (Applied Biosystems model 394) using standard phosphoramidite chemistry with oxidation by iodine.

5 Phosphorothioates (P=S) are synthesized similar to phosphodiester oligonucleotides with the following exceptions: thiation was effected by utilizing a 10% w/v solution of 3H-1,2-benzodithiole-3-one 1,1-dioxide in acetonitrile for the oxidation of the phosphite linkages.

10 The thiation reaction step time was increased to 180 sec and preceded by the normal capping step. After cleavage from the CPG column and deblocking in concentrated ammonium hydroxide at 55°C (12-16 hr), the oligonucleotides were recovered by precipitating with >3 volumes of ethanol from a 1 M NH₄OAc
15 solution. Phosphinate oligonucleotides are prepared as described in U.S. Patent 5,508,270, herein incorporated by reference.

Alkyl phosphonate oligonucleotides are prepared as described in U.S. Patent 4,469,863, herein incorporated by
20 reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference.

Phosphoramidite oligonucleotides are prepared as
25 described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and PCT/US93/06976 (published as WO 94/17093 and WO 94/02499,
30 respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

RTS-0396

-87-

PATENT

Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

5 Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both herein incorporated by reference.

Example 3

Oligonucleoside Synthesis

10 Methylenemethylimino linked oligonucleosides, also identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked
15 oligonucleosides, and methyleneaminocarbonyl linked oligonucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023,
20 5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and 5,264,564, herein incorporated by reference.

25 Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

Example 4

30 PNA Synthesis

Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential

RTS-0396

-88-

PATENT

Applications, *Bioorganic & Medicinal Chemistry*, 1996, 4, 5-23. They may also be prepared in accordance with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

5

Example 5**Synthesis of Chimeric Oligonucleotides**

Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or "wingmers".

**[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric
Phosphorothioate Oligonucleotides**

Chimeric oligonucleotides having 2'-O-alkyl phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 394, as above.

Oligonucleotides are synthesized using the automated synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by incorporating coupling steps with increased reaction times for the 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite. The fully protected oligonucleotide is cleaved from the support and deprotected in concentrated ammonia (NH₄OH) for 12-16 hr at

RTS-0396

-89-

PATENT

55°C. The deprotected oligo is then recovered by an appropriate method (precipitation, column chromatography, volume reduced *in vacuo* and analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by
5 mass spectrometry.

[2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-(Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides

10 [2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

15

[2'-O-(2-Methoxyethyl)Phosphodiester]--[2'-deoxy Phosphorothioate]--[2'-O-(2-Methoxyethyl) Phosphodiester] Chimeric Oligonucleotides

[2'-O-(2-methoxyethyl phosphodiester)]--[2'-deoxy
20 phosphorothioate]--[2'-O-(methoxyethyl) phosphodiester] chimeric oligonucleotides are prepared as per the above procedure for the 2'-O-methyl chimeric oligonucleotide with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites, oxidation with iodine to generate the
25 phosphodiester internucleotide linkages within the wing portions of the chimeric structures and sulfurization utilizing 3,4-dithiolane-2-one 1,1 dioxide (Beaucage Reagent) to generate the phosphorothioate internucleotide linkages for the center gap.

30 Other chimeric oligonucleotides, chimeric oligonucleosides and mixed chimeric oligonucleotides/oligonucleosides are synthesized according to United States patent 5,623,065, herein incorporated by

RTS-0396

-90-

PATENT

reference.

Example 6

Oligonucleotide Isolation

5 After cleavage from the controlled pore glass solid support and deblocking in concentrated ammonium hydroxide at 55°C for 12-16 hours, the oligonucleotides or oligonucleosides are recovered by precipitation out of 1 M NH₄OAc with >3 volumes of ethanol. Synthesized oligonucleotides were
10 analyzed by electrospray mass spectroscopy (molecular weight determination) and by capillary gel electrophoresis and judged to be at least 70% full length material. The relative amounts of phosphorothioate and phosphodiester linkages obtained in the synthesis was determined by the ratio of
15 correct molecular weight relative to the -16 amu product (+/- 32 +/-48). For some studies oligonucleotides were purified by HPLC, as described by Chiang et al., *J. Biol. Chem.* **1991**, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC
20 purified material.

Example 7

Oligonucleotide Synthesis - 96 Well Plate Format

25 Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a 96-well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization
30 utilizing 3,4-dithiolane-2-one 1,1-dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster

RTS-0396

-91-

PATENT

City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per standard or patented methods. They are utilized as base protected beta-cyanoethyl diisopropyl phosphoramidites.

5 Oligonucleotides were cleaved from support and deprotected with concentrated NH_4OH at elevated temperature (55-60°C) for 12-16 hours and the released product then dried *in vacuo*. The dried product was then re-suspended in sterile water to afford a master plate from which all analytical and
10 test plate samples are then diluted utilizing robotic pipettors.

Example 8

15 Oligonucleotide Analysis - 96-Well Plate Format

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual products was evaluated by capillary electrophoresis (CE) in
20 either the 96-well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test
25 plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

30 Example 9

Cell culture and oligonucleotide treatment

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types

RTS-0396

-92-

PATENT

provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following cell types are provided for illustrative purposes, but other
5 cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, ribonuclease protection assays, or RT-PCR.

10

T-24 cells:

The human transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in
15 complete McCoy's 5A basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, CA), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, CA). Cells were routinely passaged by
20 trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates
25 and treated similarly, using appropriate volumes of medium and oligonucleotide.

A549 cells:

The human lung carcinoma cell line A549 was obtained
30 from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media (Invitrogen Corporation, Carlsbad, CA) supplemented with 10% fetal calf serum (Invitrogen Corporation, Carlsbad, CA),

RTS-0396

-93-

PATENT

penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Invitrogen Corporation, Carlsbad, CA). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence.

5

NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville, MD). NHDFs were routinely maintained in Fibroblast Growth Medium

10 (Clonetics Corporation, Walkersville, MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

HEK cells:

15 Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville, MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics Corporation, Walkersville, MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10
20 passages as recommended by the supplier.

Jurkat cells:

The human Jurkat cell line was obtained from the American Type Culture Collection (ATCC) (Manassas, VA).

25 Jurkat cells were routinely cultured in RPMI Medium 1640 (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 20% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by aspirating media that contained excess cells and replenishing
30 with new media.

For electroporation, cells were diluted to 5×10^6 cells/mL and placed into 1 mm electroporation cuvettes.

Electroporation is performed by treating with $10 \mu\text{M}$ oligonucleotide, at 90 Volts for 9 msec. The entire

RTS-0396

-94-

PATENT

electroporated samples are then placed into 500 μ L of RPMI Medium 1640 in 24-well plates. Plates are then left overnight.

Each sample was then divided into two 250 μ L samples and spun down on poly-D-lysine (Sigma) coated 96-well plates (Falcon). Cells were then washed and lysed in 150 μ L RLT. Following the lysis step, RNA from the cells was isolated and quantitated as described in other examples herein.

10

Differentiated 3T3-L1 cells:

The mouse embryonic adipocyte cell line 3T3-L1 was obtained from the American Type Culture Collection (Manassas, VA). 3T3-L1 cells were differentiated by culturing for three days in the presence of 400nM insulin, 250nM dexamethasone and 0.5mM IBMX (Sigma). Differentiated 3T3L1 cells were then routinely cultured in DMEM, high glucose (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum, 100 units per ml penicillin, 100 micrograms per ml streptomycin (Gibco/Life Technologies, Gaithersburg, MD), 400nM bovine insulin (Sigma), 125mM dexamethasone , 0.5mM IBMX, and fungizone. Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 10000 cells/well for use in RT-PCR analysis.

30

For Northern blotting or other analyses, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

Treatment with antisense compounds:

When cells reached 70% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates,

RTS-0396

-95-

PATENT

wells were washed once with 100 μ L OPTI-MEMTM-1 reduced-serum medium (Invitrogen Corporation, Carlsbad, CA) and then treated with 130 μ L of OPTI-MEMTM-1 containing 3.75 μ g/mL LIPOFECTINTM (Invitrogen Corporation, Carlsbad, CA) and the
5 desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

The concentration of oligonucleotide used varies from cell line to cell line. To determine the optimal
10 oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. For human cells the positive control oligonucleotide is selected from either ISIS 13920 (**TCCGTCATCGCTCCTCAGGG**, SEQ ID NO: 1) which is targeted to
15 human H-ras, or ISIS 18078, (**GTGCGCGCGAGCCCGAAATC**, SEQ ID NO: 2) which is targeted to human Jun-N-terminal kinase-2 (JNK2). Both controls are 2'-O-methoxyethyl gapmers (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone. For mouse or rat cells the positive control
20 oligonucleotide is ISIS 15770, **ATGCATTCTGCCCCCAAGGA**, SEQ ID NO: 3, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of positive control oligonucleotide that results in 80% inhibition of c-
25 Ha-ras (for ISIS 13920) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that
30 results in 60% inhibition of H-ras or c-raf mRNA is then utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition

RTS-0396

-96-

PATENT

is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments. The concentrations of antisense oligonucleotides used herein are from 50 nM to 300 nM.

5

Example 10**Analysis of oligonucleotide inhibition of resistin expression**

Antisense modulation of resistin expression can be assayed in a variety of ways known in the art. For example, resistin mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred. RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. The preferred method of RNA analysis of the present invention is the use of total cellular RNA as described in other examples herein. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions.

Protein levels of resistin can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to resistin can be identified and obtained from a variety of sources, such as the MSRS catalog

RTS-0396

-97-

PATENT

of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods.

Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997). Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997).

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998). Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997). Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991).

Example 11

Poly(A)+ mRNA isolation

Poly(A)+ mRNA was isolated according to Miura et al., (*Clin. Chem.*, 1996, 42, 1758-1764). Other methods for poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., (*Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993). Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 60 μ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was

RTS-0396

-98-

PATENT

added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55 μ L of lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes

5 at room temperature, washed 3 times with 200 μ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to remove excess wash buffer and then air-dried for 5 minutes. 60 μ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to

10 70°C, was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.

Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all

15 solutions.

Example 12

Total RNA Isolation

Total RNA was isolated using an RNEASY 96™ kit and

20 buffers purchased from Qiagen Inc. (Valencia, CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 150 μ L Buffer RLT was added to each well and the plate vigorously

25 agitated for 20 seconds. 150 μ L of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source.

30 Vacuum was applied for 1 minute. 500 μ L of Buffer RW1 was added to each well of the RNEASY 96™ plate and incubated for

RTS-0396

-99-

PATENT

15 minutes and the vacuum was again applied for 1 minute. An additional 500 μ L of Buffer RW1 was added to each well of the RNEASY 96TM plate and the vacuum was applied for 2 minutes. 1 mL of Buffer RPE was then added to each well of the RNEASY
5 96TM plate and the vacuum applied for a period of 90 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 3 minutes. The plate was then removed from the QIAVACTM manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVACTM
10 manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 170 μ L water into each well, incubating 1 minute, and then applying the vacuum for 3 minutes.

The repetitive pipetting and elution steps may be
15 automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

20

Example 13**Real-time Quantitative PCR Analysis of resistin mRNA Levels**

Quantitation of resistin mRNA levels was determined by
25 real-time quantitative PCR using the ABI PRISMTM 7700 Sequence Detection System (PE-Applied Biosystems, Foster City, CA) according to manufacturer's instructions. This is a closed-tube, non-gel-based, fluorescence detection system which allows high-throughput quantitation of polymerase chain
30 reaction (PCR) products in real-time. As opposed to standard PCR in which amplification products are quantitated after the PCR is completed, products in real-time quantitative PCR are

RTS-0396

-100-

PATENT

quantitated as they accumulate. This is accomplished by including in the PCR reaction an oligonucleotide probe that anneals specifically between the forward and reverse PCR primers, and contains two fluorescent dyes. A reporter dye (e.g., FAM or JOE, obtained from either PE-Applied Biosystems, Foster City, CA, Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 5' end of the probe and a quencher dye (e.g., TAMRA, obtained from either PE-Applied Biosystems, Foster City, CA, Operon Technologies Inc., Alameda, CA or Integrated DNA Technologies Inc., Coralville, IA) is attached to the 3' end of the probe. When the probe and dyes are intact, reporter dye emission is quenched by the proximity of the 3' quencher dye. During amplification, annealing of the probe to the target sequence creates a substrate that can be cleaved by the 5'-exonuclease activity of Taq polymerase. During the extension phase of the PCR amplification cycle, cleavage of the probe by Taq polymerase releases the reporter dye from the remainder of the probe (and hence from the quencher moiety) and a sequence-specific fluorescent signal is generated. With each cycle, additional reporter dye molecules are cleaved from their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification reaction. In multiplexing, both the target gene and the

RTS-0396

-101-

PATENT

internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of primer-probe sets specific for GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed multiplexable. Other methods of PCR are also known in the art.

PCR reagents were obtained from Invitrogen Corporation, (Carlsbad, CA). RT-PCR reactions were carried out by adding 20 μ L PCR cocktail (2.5x PCR buffer (-MgCl₂), 6.6 mM MgCl₂, 375 μ M each of dATP, dCTP, dGTP and dTTP, 375 nM each of forward primer and reverse primer, 125 nM of probe, 4 Units RNase inhibitor, 1.25 Units PLATINUM® Taq, 5 Units MuLV reverse transcriptase, and 2.5x ROX dye) to 96-well plates containing 30 μ L total RNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the PLATINUM® Taq, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

Gene target quantities obtained by real time RT-PCR are normalized using either the expression level of GAPDH, a gene whose expression is constant, or by quantifying total RNA using RiboGreen™ (Molecular Probes, Inc. Eugene, OR). GAPDH expression is quantified by real time RT-PCR, by being run

RTS-0396

-102-

PATENT

simultaneously with the target, multiplexing, or separately. Total RNA is quantified using RiboGreenTM RNA quantification reagent from Molecular Probes. Methods of RNA quantification by RiboGreenTM are taught in Jones, L.J., et al, (Analytical
5 Biochemistry, 1998, 265, 368-374).

In this assay, 170 μ L of RiboGreenTM working reagent (RiboGreenTM reagent diluted 1:350 in 10mM Tris-HCl, 1 mM EDTA, pH 7.5) is pipetted into a 96-well plate containing 30 μ L purified, cellular RNA. The plate is read in a CytoFluor
10 4000 (PE Applied Biosystems) with excitation at 480nm and emission at 520nm.

Probes and primers to human resistin were designed to hybridize to a human resistin sequence, using published sequence information (GenBank accession number NM_020415.1,
15 incorporated herein as SEQ ID NO:4). For human resistin the PCR primers were:

forward primer: AAGCCATCAATGAGAGGATCCA (SEQ ID NO: 5)
reverse primer: TCCAGGCCAATGCTGCTTA (SEQ ID NO: 6) and the
PCR probe was: FAM-TCGCCGGCTCCCTAATATTTAGGGCA-TAMRA
20 (SEQ ID NO: 7) where FAM is the fluorescent dye and TAMRA is the quencher dye. For human GAPDH the PCR primers were:
forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO:8)
reverse primer: GAAGATGGTGATGGGATTTTC (SEQ ID NO:9) and the
PCR probe was: 5' JOE-CAAGCTTCCCGTTCTCAGCC- TAMRA 3' (SEQ ID
25 NO: 10) where JOE is the fluorescent reporter dye and TAMRA is the quencher dye.

Probes and primers to mouse resistin were designed to hybridize to a mouse resistin sequence, using published sequence information (GenBank accession number 1783_080,
30 incorporated herein as SEQ ID NO:11). For mouse resistin the PCR primers were:

forward primer: TCGTGGGACATTCGTGAAGA (SEQ ID NO:12)
reverse primer: CGGGCTGCTGTCCAGTCT (SEQ ID NO: 13) and the

RTS-0396

-103-

PATENT

PCR probe was: FAM-AAGTGTGTCCTGCTGCAAGGA-TAMRA
(SEQ ID NO: 14) where FAM is the fluorescent reporter dye and
TAMRA is the quencher dye. For mouse GAPDH the PCR primers
were:

- 5 forward primer: GGCAAATTCAACGGCACAGT(SEQ ID NO:15)
reverse primer: GGGTCTCGCTCCTGGAAGAT(SEQ ID NO:16) and the
PCR probe was: 5' JOE-AAGGCCGAGAATGGGAAGCTTGTTCATC- TAMRA 3'
(SEQ ID NO: 17) where JOE is the fluorescent reporter dye and
TAMRA is the quencher dye.

10

Example 14**Northern blot analysis of resistin mRNA levels**

- Eighteen hours after antisense treatment, cell
15 monolayers were washed twice with cold PBS and lysed in 1 mL
RNAZOL™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA was
prepared following manufacturer's recommended protocols.
Twenty micrograms of total RNA was fractionated by
electrophoresis through 1.2% agarose gels containing 1.1%
20 formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon,
OH). RNA was transferred from the gel to HYBOND™-N+ nylon
membranes (Amersham Pharmacia Biotech, Piscataway, NJ) by
overnight capillary transfer using a Northern/Southern
Transfer buffer system (TEL-TEST "B" Inc., Friendswood, TX).
25 RNA transfer was confirmed by UV visualization. Membranes
were fixed by UV cross-linking using a STRATALINKER™ UV
Crosslinker 2400 (Stratagene, Inc, La Jolla, CA) and then
probed using QUICKHYB™ hybridization solution (Stratagene, La
Jolla, CA) using manufacturer's recommendations for stringent
30 conditions.

To detect human resistin, a human resistin specific
probe was prepared by PCR using the forward primer

RTS-0396

-104-

PATENT

AAGCCATCAATGAGAGGATCCA (SEQ ID NO: 5) and the reverse primer TCCAGGCCAATGCTGCTTA (SEQ ID NO: 6). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

To detect mouse resistin, a mouse resistin specific probe was prepared by PCR using the forward primer TCGTGGGACATTCGTGAAGA (SEQ ID NO: 12) and the reverse primer CGGGCTGCTGTCCAGTCT (SEQ ID NO: 13). To normalize for variations in loading and transfer efficiency membranes were stripped and probed for mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels in untreated controls.

Example 15

Antisense inhibition of human resistin expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human resistin RNA, using published sequences (GenBank accession number NM_020415.1, incorporated herein as SEQ ID NO: 4, and the complement of residues 116001-118000 of GenBank accession number AC008763.5, incorporated herein as SEQ ID NO: 18). The oligonucleotides are shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length,

RTS-0396

-105-

PATENT

composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human resistin mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments in which Jurkat cells were treated with the oligonucleotides of the present invention. If present, "N.D." indicates "no data".

Table 1

Inhibition of human resistin mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO
165438	Start Codon	4	17	gagagctttcatcctgcagg	55	19
165440	Start Codon	4	27	ggaggagacagagagctttc	62	20
165442	Coding	4	60	tgctagacaccaacagcccc	0	21
165444	Coding	4	66	gggtcttgctagacaccaac	0	22
165763	Coding	4	73	gagcacagggctcttgctaga	0	23
165765	Coding	4	79	tccatggagcacagggctctt	3	24
165767	Coding	4	91	ttgatggcttcttccatgga	0	25
165769	Coding	4	97	ctctcattgatggcttcttc	55	26
165771	Coding	4	108	cctcctggatcctctcattg	81	27
165773	Coding	4	116	gccggcgacctcctggatcc	91	28
165775	Coding	4	122	tagggagccggcgacctcct	58	29
165777	Coding	4	125	tattagggagccggcgacct	55	30
165780	Coding	4	140	gcttattgccctaaatatta	30	31
165782	Coding	4	151	aggccaatgctgcttattgc	96	32
165784	Coding	4	154	tccaggccaatgctgcttat	88	33
165786	Coding	4	159	ggcactccaggccaatgctg	81	34
165788	Coding	4	226	caagtgcagccggtgacggc	0	35
165790	Coding	4	233	ggagccacaagtgcagccgg	28	36
165792	Coding	4	239	acaggcggagccacaagtgc	13	37
165794	Coding	4	255	gcacatcccacgagccacag	57	38
165796	Coding	4	279	ggcagtgcacatgtggtctcg	41	39

RTS-0396

-106-

PATENT

165798	Coding	4	286	gcgcactggcagtgacatgt	47	40
165800	Coding	4	291	tgcccgcgactggcagtga	61	41
165802	Coding	4	301	gtccagtccatgcccgcgca	11	42
165804	Coding	4	328	ggctgcacacgacagcagcg	0	43
165806	Stop Codon	4	340	gcgcgacctcagggctgcac	83	44
165808	3'UTR	4	389	aacccctccggaectggagc	57	45
165810	3'UTR	4	407	tatttccagctcccccgcaa	12	46
165812	3'UTR	4	412	aggtttatttccagctcccc	54	47
165814	3'UTR	4	418	atctccaggtttatttccag	64	48
165816	3'UTR	4	423	tcatcatctccaggtttatt	74	49
165818	3'UTR	4	428	catcatcatctccaggt	88	50
165820	Exon: Intron Junction	18	369	ggctctcacttagggagccg	20	51
165830	Intron: Exon Junction	18	1142	ggcgaagcctgcagcccga	0	52

As shown in Table 1, SEQ ID NOs 19, 20, 26, 27, 28, 29, 30, 32, 33, 34, 38, 41, 44, 45, 47, 48, 49 and 50

- 5 demonstrated at least 50% inhibition of human resistin expression in this assay and are therefore preferred. The target sites to which these preferred sequences are complementary are herein referred to as "preferred target regions" and are therefore preferred sites for targeting by
- 10 compounds of the present invention. These preferred target regions are shown in Table 3. The sequences represent the reverse complement of the preferred antisense compounds shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number of the corresponding target nucleic acid.
- 15 Also shown in Table 3 is the species in which each of the preferred target regions was found.

Example 16

- 20 **Antisense inhibition of mouse resistin expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap.**

In accordance with the present invention, a second

RTS-0396

-107-

PATENT

series of oligonucleotides were designed to target different regions of the mouse resistin RNA, using published sequences (the sequence presented in Figure 1: Steppan et al., *Nature*, **2001**, 409, 307-312, incorporated herein as SEQ ID NO: 11, and an assembly of contigs from GenBank accession number AC079491.1, incorporated herein as SEQ ID NO: 53). The oligonucleotides are shown in Table 2. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 2 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on mouse resistin mRNA levels by quantitative real-time PCR as described in other examples herein. Data are averages from two experiments in which differentiated 3T3-L1 cells were treated with the oligonucleotides of the present invention. The positive control for each datapoint is identified in the table by sequence ID number. If present, "N.D." indicates "no data".

Table 2

Inhibition of mouse resistin mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

RTS-0396

-108-

PATENT

ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	% INHIB	SEQ ID NO	CONTROL SEQ ID NO
165359	5'UTR	11	14	attagctcctgtcccacagc	36	54	1
165360	5'UTR	11	18	gggtattagctcctgtccca	39	55	1
165361	5'UTR	11	28	actcagttctgggtattagc	21	56	1
165362	5'UTR	11	41	ttagcaggacacaactcagt	6	57	1
165363	5'UTR	11	47	gaggacttagcaggacacaa	14	58	1
165364	5'UTR	11	51	ggcagaggacttagcaggac	9	59	1
165365	5'UTR	11	60	tgggtacgtggcagaggact	40	60	1
165366	Start Codon	11	68	tcatcccgtgggtacgtggc	5	61	1
165367	Start Codon	11	76	aaggttcttcatcccgtggg	19	62	1
165368	Start Codon	11	84	ggaaatgaaaggttcttcat	4	63	1
165369	Coding	11	116	gttcaggagacaaggaagaaa	17	64	1
165370	Coding	11	125	agcccagcagttcagggaca	34	65	1
165371	Coding	11	129	ctggagcccagcagttcagg	0	66	1
165372	Coding	11	134	gcatgctggagcccagcagt	3	67	1
165373	Coding	11	139	cagtggcatgctggagccca	15	68	1
165374	Coding	11	151	atcgatgggacacagtggca	52	69	1
165375	Coding	11	155	cttcatcgatgggacacagt	8	70	1
165376	Coding	11	162	tcgatggcttcatcgatggg	0	71	1
165377	Coding	11	172	gatcttcttgcgatggctt	26	72	1
165378	Coding	11	191	gggagtgaagtcttgtttg	8	73	1
165379	Coding	11	194	acagggagttgaagtcttgt	21	74	1
165380	Coding	11	197	gaaacaggagttgaagtct	14	75	1
165381	Coding	11	204	gcatttggaaacaggagtt	30	76	1
165382	Coding	11	209	ttattgcatttggaaacagg	0	77	1
165383	Coding	11	211	ctttattgcatttggaaaca	20	78	1
165384	Coding	11	220	gccaatgttctttattgcat	35	79	1
165385	Coding	11	228	caatttaagccaatgttctt	8	80	1
165386	Coding	11	229	gcaatttaagccaatgttct	0	81	1
165387	Coding	11	235	tgtccagcaatttaagccaa	46	82	1
165388	Coding	11	240	gagactgtccagcaatttaa	52	83	1
165389	Coding	11	252	ttccctcttgaggagactgt	0	84	1
165390	Coding	11	258	gccaacttccctcttgaggga	66	85	1
165391	Coding	11	259	ggccaacttccctcttgagg	38	86	1
165392	Coding	11	264	caggaggccaacttccctct	24	87	1
165393	Coding	11	267	gggcaggaggccaacttccc	11	88	1
165394	Coding	11	282	actgctgtgccttctgggca	0	89	1
165395	Coding	11	299	cacaggagcagctcaagact	3	90	1
165396	Coding	11	322	gtcccacgagccacaggcag	12	91	1
165397	Coding	11	324	atgtcccacgagccacaggc	25	92	1
165398	Coding	11	332	cttcacgaatgtcccacgag	37	93	1
165399	Coding	11	338	ctttttcttcacgaatgtcc	25	94	1
165400	Coding	11	354	cactggcagtgacacacttt	61	95	1
165401	Coding	11	358	tgcactctggcagtgacaca	67	96	1
165402	Coding	11	363	atccttgacactggcagtg	8	97	1
165403	Coding	11	367	gtctatccttgacactggc	70	98	1
165404	Coding	11	373	tgtccagtcctatccttgac	58	99	1
165405	Coding	11	377	ctgctgtccagtcctatcctt	66	100	1
165406	Coding	11	384	cagcgggctgctgtccagtc	69	101	1
165407	Coding	11	388	acagcagcgggctgctgtcc	40	102	1
165408	Coding	11	398	cctgcagcttacagcagcgg	3	103	1
165409	Coding	11	401	cgacctgcagcttacagcag	0	104	1

RTS-0396

-109-

PATENT

165410	Coding	11	406	ggaagcgacctgcagcttac	2	105	1
165411	Stop Codon	11	409	tcaggaagcgacctgcagct	0	106	1
165412	Stop Codon	11	418	tccccgacatcaggaagcga	10	107	1
165413	Stop Codon	11	424	ctcacttccccgacatcagg	0	108	1
165414	3'UTR	11	437	gctggaaaccacgctcactt	50	109	1
165415	3'UTR	11	441	ctgtgctggaaaccacgctc	6	110	1
165416	3'UTR	11	456	tacaggaacgggtggctgtg	0	111	1
165417	3'UTR	11	468	catctctggagctacaggaa	18	112	1
165418	3'UTR	11	470	gacatctctggagctacagg	23	113	1
165419	3'UTR	11	474	atcagacatctctggagcta	22	114	1
165420	3'UTR	11	479	aggacatcagacatctctgg	24	115	1
165421	3'UTR	11	486	agaccggaggacatcagaca	26	116	1
165422	3'UTR	11	529	tgcttggtgtgtggattcg	62	117	1
165423	3'UTR	11	531	tgtgcttggtgtgtggattcg	78	118	1
165424	Exon: Intron Junction	53	8737	tatcacttaccgtggcagag	10	119	1
165425	Intron	53	8796	atggatggacattcagcagc	31	120	1
165426	Intron: Exon Junction	53	8899	cccgtgggtactgcaagaga	23	121	1
165427	Intron	53	9350	acgttcacggtaaaatattt	1	122	1
165428	Intron	53	9486	gattctgtctcaacaaagca	42	123	1
165429	Intron	53	9630	cccagaacccatttagaagc	32	124	1
165430	Intron: Exon Junction	53	10143	actgctgtgcctgcaaggaa	6	125	1
165431	Exon: Intron Junction	53	10285	ctcaactgaccgacatcagg	10	126	1
165432	Intron	53	10307	cataagaaggacaagctcag	0	127	1
165433	Intron	53	11957	ctccatggcttctgcatcag	33	128	1
165434	Intron	53	12110	cataagatccactacagggc	21	129	1
165435	Intron	53	12692	taaccattgacccatctttc	0	130	1
165436	Intron: Exon Junction	53	12724	ctcacttcccctgaaaaagc	5	131	1

As shown in Table 2, SEQ ID NOs 60, 69, 82, 83, 85, 95,
5 96, 98, 99, 100, 101, 102, 109, 117, 118 and 123 demonstrated
at least 40% inhibition of mouse resistin expression in this
experiment and are therefore preferred. The target sites to
which these preferred sequences are complementary are herein
referred to as "preferred target regions" and are therefore
10 preferred sites for targeting by compounds of the present

RTS-0396

-110-

PATENT

invention. These preferred target regions are shown in Table 3. The sequences represent the reverse complement of the preferred antisense compounds shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number of the corresponding target nucleic acid. Also shown in Table 3 is the species in which each of the preferred target regions was found.

10

Table 3
Sequence and position of preferred target regions identified in resistin.

SITEID	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	REV COMP OF SEQ ID	ACTIVE IN	SEQ ID NO
80897	4	17	cctgcaggatgaaagctctc	19	<i>H. sapiens</i>	132
80899	4	27	gaaagctctctgtctcctcc	20	<i>H. sapiens</i>	133
80911	4	97	gaagaagccatcaatgagag	26	<i>H. sapiens</i>	134
80913	4	108	caatgagaggatccaggagg	27	<i>H. sapiens</i>	135
80915	4	116	ggatccaggaggctcgccggc	28	<i>H. sapiens</i>	136
80917	4	122	aggaggctcgccggctcccta	29	<i>H. sapiens</i>	137
80919	4	125	aggtcgccggctccctaata	30	<i>H. sapiens</i>	138
80924	4	151	gcaataagcagcattggcct	32	<i>H. sapiens</i>	139
80926	4	154	ataagcagcattggcctgga	33	<i>H. sapiens</i>	140
80928	4	159	cagcattggcctggagtgcc	34	<i>H. sapiens</i>	141
80936	4	255	ctgtggctcgtgggatgtgc	38	<i>H. sapiens</i>	142
80942	4	291	tcaactgccagtgcgcgggca	41	<i>H. sapiens</i>	143
80948	4	340	gtgcagccctgaggtcgcg	44	<i>H. sapiens</i>	144
80950	4	389	gctccagggtccggaggggtt	45	<i>H. sapiens</i>	145
80954	4	412	ggggagctggaaataaacct	47	<i>H. sapiens</i>	146
80956	4	418	ctggaaataaacctggagat	48	<i>H. sapiens</i>	147
80958	4	423	aataaacctggagatgatga	49	<i>H. sapiens</i>	148
80960	4	428	acctggagatgatgatgatg	50	<i>H. sapiens</i>	149
80824	11	60	agtcctctgccacgtaccca	60	<i>M. musculus</i>	150
80833	11	151	tgccactgtgtcccatcgat	69	<i>M. musculus</i>	151
80846	11	235	ttggcttaaattgctggaca	82	<i>M. musculus</i>	152
80847	11	240	ttaaattgctggacagtctc	83	<i>M. musculus</i>	153
80849	11	258	tcctccagaggggaagtggc	85	<i>M. musculus</i>	154
80859	11	354	aaagtgtgtcactgccagt	95	<i>M. musculus</i>	155
80860	11	358	tgtgtcactgccagtgtgca	96	<i>M. musculus</i>	156
80862	11	367	gccagtgtgcaaggatagac	98	<i>M. musculus</i>	157
80863	11	373	gtgcaaggatagactggaca	99	<i>M. musculus</i>	158
80864	11	377	aaggatagactggacagcag	100	<i>M. musculus</i>	159
80865	11	384	gactggacagcagcccgctg	101	<i>M. musculus</i>	160
80866	11	388	ggacagcagcccgctgctgt	102	<i>M. musculus</i>	161
80873	11	437	aagtgagcgtgggtttccagc	109	<i>M. musculus</i>	162
80881	11	529	cgcgaaatccacacacaagca	117	<i>M. musculus</i>	163

RTS-0396

-111-

PATENT

80882	11	531	cgaatccacacacaagcaca	118	<i>M. musculus</i>	164
80887	53	9486	tgctttgttgagacagaatc	123	<i>M. musculus</i>	165

As these "preferred target regions" have been found by
5 experimentation to be open to, and accessible for,
hybridization with the antisense compounds of the present
invention, one of skill in the art will recognize or be able
to ascertain, using no more than routine experimentation,
further embodiments of the invention that encompass other
10 compounds that specifically hybridize to these sites and
consequently inhibit the expression of resistin.

In one embodiment, the "preferred target region" may be
employed in screening candidate antisense compounds.
"Candidate antisense compounds" are those that inhibit the
15 expression of a nucleic acid molecule encoding resistin and
which comprise at least an 8-nucleobase portion which is
complementary to a preferred target region. The method
comprises the steps of contacting a preferred target region
of a nucleic acid molecule encoding resistin with one or more
20 candidate antisense compounds, and selecting for one or more
candidate antisense compounds which inhibit the expression of
a nucleic acid molecule encoding resistin. Once it is shown
that the candidate antisense compound or compounds are
capable of inhibiting the expression of a nucleic acid
25 molecule encoding resistin, the candidate antisense compound
may be employed as an antisense compound in accordance with
the present invention.

According to the present invention, antisense compounds
include ribozymes, external guide sequence (EGS),
30 oligonucleotides (oligozymes), and other short catalytic RNAs
or catalytic oligonucleotides which hybridize to the target
nucleic acid and modulate its expression.

RTS-0396

-112-

PATENT

Example 17**Western blot analysis of resistin protein levels**

5 Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 ul/well), boiled for 5 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for
10 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to resistin is used, with a radiolabeled or fluorescently labeled secondary antibody directed against the primary antibody species. Bands are visualized using a PHOSPHORIMAGER™
15 (Molecular Dynamics, Sunnyvale CA).

RTS-0396

-113-

PATENT

What is claimed is:

1. A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding resistin, wherein said compound specifically hybridizes with said nucleic acid molecule encoding resistin and inhibits the expression of resistin.
2. The compound of claim 1 which is an antisense oligonucleotide.
3. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
4. The compound of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.
5. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
6. The compound of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
7. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
8. The compound of claim 7 wherein the modified nucleobase is a 5-methylcytosine.
9. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
10. A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of a preferred target region on a nucleic acid molecule encoding resistin.
11. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
12. The composition of claim 11 further comprising a

RTS-0396

-114-

PATENT

colloidal dispersion system.

13. The composition of claim 11 wherein the compound is an antisense oligonucleotide.

14. A method of inhibiting the expression of resistin in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of resistin is inhibited.

15. A method of treating an animal having a disease or condition associated with resistin comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of resistin is inhibited.

16. A method of screening for an antisense compound, the method comprising the steps of:

a. contacting a preferred target region of a nucleic acid molecule encoding resistin with one or more candidate antisense compounds, said candidate antisense compounds comprising at least an 8-nucleobase portion which is complementary to said preferred target region, and

b. selecting for one or more candidate antisense compounds which inhibit the expression of a nucleic acid molecule encoding resistin.

17. The method of claim 15 wherein the disease or condition is a metabolic disorder.

18. The method of claim 17 wherein the metabolic disorder is diabetes.

19. The method of claim 17 wherein the metabolic disorder is obesity.

20. The method of claim 15 wherein the disease or condition is atherosclerosis.

RTS-0396

-1-

PATENT

SEQUENCE LISTING

<110> Sanjay Bhanot

Susan M. Freier

<120> ANTISENSE MODULATION OF RESISTIN EXPRESSION

<130> RTS-0396

<160> 165

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 1

tccgtcatcg ctcctcaggg

20

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 2

gtgcgcgcga gcccgaatc

20

<210> 3

RTS-0396

-2-

PATENT

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 3

atgcattctg cccccaagga

20

<210> 4

<211> 457

<212> DNA

<213> H. sapiens

<220>

<220>

<221> CDS

<222> (25)...(351)

<400> 4

agccccaccga gaggcgcctg cagg atg aaa gct ctc tgt ctc ctc ctc 51

Met Lys Ala Leu Cys Leu Leu Leu Leu

1

5

cct gtc ctg ggg ctg ttg gtg tct agc aag acc ctg tgc tcc atg gaa 99

Pro Val Leu Gly Leu Leu Val Ser Ser Lys Thr Leu Cys Ser Met Glu

10

15

20

25

gaa gcc atc aat gag agg atc cag gag gtc gcc ggc tcc cta ata ttt 147

Glu Ala Ile Asn Glu Arg Ile Gln Glu Val Ala Gly Ser Leu Ile Phe

30

35

40

agg gca ata agc agc att ggc ctg gag tgc cag agc gtc acc tcc agg 195

Arg Ala Ile Ser Ser Ile Gly Leu Glu Cys Gln Ser Val Thr Ser Arg

45

50

55

RTS-0396

-3-

PATENT

ggg gac ctg gct act tgc ccc cga ggc ttc gcc gtc acc ggc tgc act 243
 Gly Asp Leu Ala Thr Cys Pro Arg Gly Phe Ala Val Thr Gly Cys Thr
 60 65 70

tgt ggc tcc gcc tgt ggc tcg tgg gat gtg cgc gcc gag acc aca tgt 291
 Cys Gly Ser Ala Cys Gly Ser Trp Asp Val Arg Ala Glu Thr Thr Cys
 75 80 85

cac tgc cag tgc gcg ggc atg gac tgg acc gga gcg cgc tgc tgt cgt 339
 His Cys Gln Cys Ala Gly Met Asp Trp Thr Gly Ala Arg Cys Cys Arg
 90 95 100 105

gtg cag ccc tga ggtcgcgcgc agcgcgtgca cagcgcgggc ggagggcggct 391

ccaggtccgg aggggttgcg ggggagctgg aaataaacct ggagatgatg atgatgatga 451

tgatgg 457

<210> 5

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 5

aagccatcaa tgagaggatc ca

22

<210> 6

<211> 19

<212> DNA

<213> Artificial Sequence

RTS-0396

-4-

PATENT

<220>

<223> PCR Primer

<400> 6

tccaggccaa tgctgctta

19

<210> 7

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 7

tcgccggctc cctaataattt agggca

26

<210> 8

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 8

gaaggtgaag gtcggagtc

19

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

RTS-0396

-5-

PATENT

<220>

<223> PCR Primer

<400> 9

gaagatggtg atgggatttc

20

<210> 10

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 10

caagcttccc gttctcagcc

20

<210> 11

<211> 591

<212> DNA

<213> M. musculus

<220>

<220>

<221> CDS

<222> (84)...(428)

<400> 11

tcaacaagaa ggagctgtgg gacaggagct aataccaga actgagttgt gtcttgctaa 60

gtcctctgcc acgtaccac ggg atg aag aac ctt tca ttt ccc ctc ctt ttc 113

Met Lys Asn Leu Ser Phe Pro Leu Leu Phe

1

5

10

RTS-0396

-6-

PATENT

ctt ttc ttc ctt gtc cct gaa ctg ctg ggc tcc agc atg cca ctg tgt 161
 Leu Phe Phe Leu Val Pro Glu Leu Leu Gly Ser Ser Met Pro Leu Cys
 15 20 25

ccc atc gat gaa gcc atc gac aag aag atc aaa caa gac ttc aac tcc 209
 Pro Ile Asp Glu Ala Ile Asp Lys Lys Ile Lys Gln Asp Phe Asn Ser
 30 35 40

ctg ttt cca aat gca ata aag aac att ggc tta aat tgc tgg aca gtc 257
 Leu Phe Pro Asn Ala Ile Lys Asn Ile Gly Leu Asn Cys Trp Thr Val
 45 50 55

tcc tcc aga ggg aag ttg gcc tcc tgc cca gaa ggc aca gca gtc ttg 305
 Ser Ser Arg Gly Lys Leu Ala Ser Cys Pro Glu Gly Thr Ala Val Leu
 60 65 70

agc tgc tcc tgt ggc tct gcc tgt ggc tcg tgg gac att cgt gaa gaa 353
 Ser Cys Ser Cys Gly Ser Ala Cys Gly Ser Trp Asp Ile Arg Glu Glu
 75 80 85 90

aaa gtg tgt cac tgc cag tgt gca agg ata gac tgg aca gca gcc cgc 401
 Lys Val Cys His Cys Gln Cys Ala Arg Ile Asp Trp Thr Ala Ala Arg
 95 100 105

tgc tgt aag ctg cag gtc gct tcc tga tgtcggggaa gtgagcgtgg 448
 Cys Cys Lys Leu Gln Val Ala Ser
 110

tttccagcac agccacccgt tctgttagct ccagagatgt ctgatgtcct ccggtctcta 508

caggcacctg cactcacgtg cgcgaatcca cacacaagca cacatactta aaaataaaac 568

aaaacaggct ggaaaaaaaaaaa aaa 591

<210> 12

<211> 20

<212> DNA

RTS-0396**-7-****PATENT**

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 12

tcgtgggaca ttcgtgaaga

20

<210> 13

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 13

cgggctgctg tccagtct

18

<210> 14

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 14

aagtgtgtca ctgccagtgt gcaagga

27

<210> 15

<211> 20

<212> DNA

RTS-0396**- 8 -****PATENT**

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 15

ggcaaattca acggcacagt

20

<210> 16

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 16

gggtctcgct cctggaagat

20

<210> 17

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Probe

<400> 17

aaggccgaga atgggaagct tgatcatc

27

<210> 18

<211> 2000

<212> DNA

RTS-0396

-9-

PATENT

<213> H. sapiens

<220>

<400> 18

gagctgcggt gcaggaattc gtgtgccgga tttggttagc tgagcccacc gagagggtaa	60
gtgacagctg ctctgcgct tgccatggca ccagcgggga ggctggggtc aaggctgagc	120
ctccatccct gtccccaca tggggggaca ggggtccagg tccaggggca gatcctactc	180
cctccatggg ccgcatcttc cccacagggc agggctgata cagctgtggg tctcttggtt	240
ccctctttca gcgcctgcag gatgaaagct ctctgtctcc tcctcctccc tgtcctgggg	300
ctgttggtgt ctagcaagac cctgtgctcc atggaagaag ccatcaatga gaggatccag	360
gaggtcgccg gctccctaag tgaggacccc ccacttgggc aagctcccca aggtctcag	420
agacctcact gatccctggc acagacctga ctccaacca gcccagcgc tcaccaaatac	480
tcctcctcaa atccaaccag atcataaatt caacccaac tccactccca accctccga	540
ctgtccccac ctatccacg gctccaaacc caatccccgc tctactcca aaccttcct	600
tactccaaaa caccgaactc aagacaggt cctggaggcc agtgagctcc tatgccaca	660
gggacctagc tccaaacca cagggctagg ggaggatggg ggagggaccg tttggtctca	720
cagctcccc tgtctccttt cctcctgccc ccagtatatt agggcaataa gcagcattgg	780
cctggagtgc cagagcgtca cctccagggg ggacctggct acttgcccc gaggtgagtg	840
caggagactg ttgtccaggc gccattttct gttccaagtc ccctgggaat gccccctccc	900
cgccacgttc cccgtgtcca gcctctaact ccctaggatc ttggtcctga ctcccagcct	960
tctccgcca ccatctggac actggtgtcc accctcactc cctgcctcca gtgccattc	1020

RTS-0396

-10-

PATENT

agtgggttga gcctccagcc gtccccgtcc ccacccccgc ccccccaacc cccctccgcg 1080

ctccccaccc ccctcccgtc cccaccctca gcctcccagc tcagagtcca cgctcctgtg 1140

ttccgggctg caggcttcgc cgtcaccggc tgcacttggtg gctccgcctg tggctcgtgg 1200

gatgtgcgcg ccgagaccac atgtcactgc cagtgcgcgg gcattggactg gaccggagcg 1260

cgctgctgtc gtgtgcagcc ctgaggctgc gcgcagcgcg tgcacagcg gggcggaggc 1320

ggctccaggt ccggaggggt tgcgggggag ctggaaataa acctggagat gatgatgatg 1380

atgatgatga tgatgatgga gcggatctga gccctgcgtg gtttcttttag taggcccgga 1440

gggactgatc tagcgtctcc aagagagtgg ggcgcgtagc tgctggaggg ggcggggaca 1500

ccgcgacttt ctactgcccc atcgcccttc ctccatggg gtctccaact gcttcctccg 1560

aaaatagggc ctgaacttcc tctagtgcgc tccccaccca aggctcatgg ctgccttcaa 1620

gaggtgacgt ctcatctttg aggctacctt gacgctcacc ctgggggtctc cgacctcccc 1680

aggaagtggc tgggtccttt tccccagtc ctcataatga ggcttcatcg aggacctggg 1740

tcagtctggg cagtggacgg gaccctccag ggccccaaaga ctccaggagc cccagggtcag 1800

ggtggaaccc tgaatcatgt ctgagcccag agctggaacc tgtaccctc acttcctacc 1860

tgcaaggagg aatccccaaag gcacaggcaa agttgggtta cggagagtca gggacgccta 1920

cctgacgtca cgcacatca caagctcagc ttttcacaca ggcaagtgc gttgtgagta 1980

gtagttaca accagataca 2000

<210> 19

<211> 20

<212> DNA

RTS-0396

-11-

PATENT

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 19

gagagctttc atcctgcagg

20

<210> 20

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 20

ggaggagaca gagagctttc

20

<210> 21

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 21

tgctagacac caacagcccc

20

<210> 22

<211> 20

<212> DNA

RTS-0396

-12-

PATENT

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 22

gggtcttgct agacaccaac

20

<210> 23

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 23

gagcacaggg tcttgctaga

20

<210> 24

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 24

tccatggagc acaggtctt

20

<210> 25

<211> 20

<212> DNA

RTS-0396**-13-****PATENT**

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 25

ttgatggcctt cttccatgga

20

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 26

ctctcattga tggcttcttc

20

<210> 27

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 27

cctcctggat cctctcattg

20

<210> 28

<211> 20

<212> DNA

RTS-0396**-14-****PATENT**

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 28

gccggcgacc tcctggatcc

20

<210> 29

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 29

tagggagccg gcgacctcct

20

<210> 30

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 30

tattagggag ccggcgacct

20

<210> 31

<211> 20

<212> DNA

RTS-0396

-15-

PATENT

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 31

gcttattgcc ctaaata

20

<210> 32

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 32

aggccaatgc tgcttattgc

20

<210> 33

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 33

tccaggccaa tgctgcttat

20

<210> 34

<211> 20

<212> DNA

RTS-0396

-16-

PATENT

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 34

ggcactccag gccaatgctg

20

<210> 35

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 35

caagtgcagc cggtagacggc

20

<210> 36

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 36

ggagccacaa gtgcagccgg

20

<210> 37

<211> 20

<212> DNA

RTS-0396

-17-

PATENT

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 37

acaggcggag ccacaagtgc

20

<210> 38

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 38

gcacatccca cgagccacag

20

<210> 39

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 39

ggcagtgaca tgtggtctcg

20

<210> 40

<211> 20

<212> DNA

RTS-0396

-18-

PATENT

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 40

gcgcactggc agtgacatgt

20

<210> 41

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 41

tgcccgcgca ctggcagtga

20

<210> 42

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 42

gtccagtcca tgcccgcgca

20

<210> 43

<211> 20

<212> DNA

RTS-0396**-19-****PATENT**

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 43

ggctgcacac gacagcagcg

20

<210> 44

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 44

gcgcgacctc agggctgcac

20

<210> 45

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 45

aacccctccg gacctggagc

20

<210> 46

<211> 20

<212> DNA

RTS-0396**-20-****PATENT**

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 46

tatttccagc tcccccgcaa

20

<210> 47

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 47

aggtttattt ccagctcccc

20

<210> 48

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 48

atctccaggt ttatttccag

20

<210> 49

<211> 20

<212> DNA

RTS-0396

-21-

PATENT

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 49

tcatcatctc caggtttatt

20

<210> 50

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 50

catcatcatc atctccaggt

20

<210> 51

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 51

ggctctcact tagggagccg

20

<210> 52

<211> 20

<212> DNA

RTS-0396

-22-

PATENT

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 52

ggcgaagcct gcagcccgga

20

<210> 53

<211> 15001

<212> DNA

<213> M. musculus

<220>

<221> unsure

<222> 11200

<223> unknown

<221> unsure

<222> 11201

<223> unknown

<221> unsure

<222> 11202

<223> unknown

<221> unsure

<222> 11203

<223> unknown

<221> unsure

<222> 11204

<223> unknown

<221> unsure

<222> 11205

RTS-0396**-23-****PATENT**

<223> unknown

<221> unsure

<222> 11206

<223> unknown

<221> unsure

<222> 11207

<223> unknown

<221> unsure

<222> 11208

<223> unknown

<221> unsure

<222> 11209

<223> unknown

<221> unsure

<222> 11210

<223> unknown

<221> unsure

<222> 11211

<223> unknown

<221> unsure

<222> 11212

<223> unknown

<221> unsure

<222> 11213

<223> unknown

<221> unsure

<222> 11214

<223> unknown

<221> unsure

RTS-0396**-24-****PATENT**

<222> 11215

<223> unknown

<221> unsure

<222> 11216

<223> unknown

<221> unsure

<222> 11217

<223> unknown

<221> unsure

<222> 11218

<223> unknown

<221> unsure

<222> 11219

<223> unknown

<221> unsure

<222> 11220

<223> unknown

<221> unsure

<222> 11221

<223> unknown

<221> unsure

<222> 11222

<223> unknown

<221> unsure

<222> 11223

<223> unknown

<221> unsure

<222> 11224

<223> unknown

RTS-0396**-25-****PATENT**

<221> unsure
<222> 11225
<223> unknown

<221> unsure
<222> 11226
<223> unknown

<221> unsure
<222> 11227
<223> unknown

<221> unsure
<222> 11228
<223> unknown

<221> unsure
<222> 11229
<223> unknown

<221> unsure
<222> 11230
<223> unknown

<221> unsure
<222> 11231
<223> unknown

<221> unsure
<222> 11232
<223> unknown

<221> unsure
<222> 11233
<223> unknown

<221> unsure
<222> 11234
<223> unknown

RTS-0396**-26-****PATENT**

<221> unsure
<222> 11235
<223> unknown

<221> unsure
<222> 11236
<223> unknown

<221> unsure
<222> 11237
<223> unknown

<221> unsure
<222> 11238
<223> unknown

<221> unsure
<222> 11239
<223> unknown

<221> unsure
<222> 11240
<223> unknown

<221> unsure
<222> 11241
<223> unknown

<221> unsure
<222> 11242
<223> unknown

<221> unsure
<222> 11243
<223> unknown

<221> unsure
<222> 11244

RTS-0396**-27-****PATENT**

<223> unknown

<221> unsure

<222> 11245

<223> unknown

<221> unsure

<222> 11246

<223> unknown

<221> unsure

<222> 11247

<223> unknown

<221> unsure

<222> 11248

<223> unknown

<221> unsure

<222> 11249

<223> unknown

<221> unsure

<222> 11250

<223> unknown

<221> unsure

<222> 11251

<223> unknown

 <221> unsure

<222> 11252

<223> unknown

<221> unsure

<222> 11253

<223> unknown

<221> unsure

RTS-0396**-28-****PATENT**

<222> 11254

<223> unknown

<221> unsure

<222> 11255

<223> unknown

<221> unsure

<222> 11256

<223> unknown

<221> unsure

<222> 11257

<223> unknown

<221> unsure

<222> 11258

<223> unknown

<221> unsure

<222> 11259

<223> unknown

<221> unsure

<222> 11260

<223> unknown

<221> unsure

<222> 11261

<223> unknown

<221> unsure

<222> 11262

<223> unknown

<221> unsure

<222> 11263

<223> unknown

RTS-0396**-29-****PATENT**

<221> unsure
<222> 11264
<223> unknown

<221> unsure
<222> 11265
<223> unknown

<221> unsure
<222> 11266
<223> unknown

<221> unsure
<222> 11267
<223> unknown

<221> unsure
<222> 11268
<223> unknown

<221> unsure
<222> 11269
<223> unknown

<221> unsure
<222> 11270
<223> unknown

<221> unsure
<222> 11271

<223> unknown

<221> unsure
<222> 11272
<223> unknown

<221> unsure
<222> 11273
<223> unknown

RTS-0396

-30-

PATENT

<221> unsure
<222> 11274
<223> unknown

<221> unsure
<222> 11275
<223> unknown

<221> unsure
<222> 11276
<223> unknown

<221> unsure
<222> 11277
<223> unknown

<221> unsure
<222> 11278
<223> unknown

<221> unsure
<222> 11279
<223> unknown

<221> unsure
<222> 11280
<223> unknown

<221> unsure
<222> 11281
<223> unknown

<221> unsure
<222> 11282
<223> unknown

<221> unsure
<222> 11283

RTS-0396**-31-****PATENT**

<223> unknown

<221> unsure

<222> 11284

<223> unknown

<221> unsure

<222> 11285

<223> unknown

<221> unsure

<222> 11286

<223> unknown

<221> unsure

<222> 11287

<223> unknown

<221> unsure

<222> 11288

<223> unknown

<221> unsure

<222> 11289

<223> unknown

<221> unsure

<222> 11290

<223> unknown

<221> unsure

<222> 11291

<223> unknown

<221> unsure

<222> 11292

<223> unknown

<221> unsure

RTS-0396

-32-

PATENT

<222> 11293

<223> unknown

<221> unsure

<222> 11294

<223> unknown

<221> unsure

<222> 11295

<223> unknown

<221> unsure

<222> 11296

<223> unknown

<221> unsure

<222> 11297

<223> unknown

<221> unsure

<222> 11298

<223> unknown

<223>

<400> 53

tcggtaccta gcacacttgt gggagaaggg aatcataggc aggggcttcc taattgacgt 60

ccacagtcta ttcgtgtata tgtgtggtgc tgggatagaa cgctggcaca ctatgcaaga 120

acttaaccct gaaccacgga ctccatccac tcaactggggg attctaggta gggactctac 180

ccctgaacca cggaccccag ccctcactg tgcaaagcta ggtggaagct cttcctttga 240

gccacaccct agcccctccc tggggcacat ctaggccgga ctctttcact gagacatagt 300

cctagcattc cacttttttt tttttttttt gaggcagggt ggtctgtttt ttgaacttgc 360

RTS-0396

-33-

PATENT

taattcaagc tagactctct ggccagtcag ccctagggat cctcctgttt ctgttctccc	420
caattaaagg cacacagttg tagaggaatt ttaatcatgg atgttctggc aagggattac	480
attcagagac cttctaggtc catgtgatct ggctggaatg cagacaagtc acaggccatt	540
aatccctctg gctggaatat agacatgcct ttaggacata cctttaatcc caaacgtgta	600
ggtaaagtta gtttgtagaa ggaagaagca tgtttgaatt gtgaacctga ttgaggggca	660
agcaaagtga caaatcgga aaatatgtga cagaatgact cagaggtagg acatgcccaa	720
ctctcacgtg aaagagaaca gtaggtatgg gtagcaggga gacagtttta ttagaacggc	780
tttacagaga gaggttccag gtgaagacag gaaaagctag agaatgagaa ggagccagaa	840
gattagaata gattgccagt gttagtgtga agccaagcaa ggcaattctg tgagaagcca	900
gtaagcttga agaagagtct gaccagtga gcctagctga accatccatc caagaactta	960
gaacaagaga gcttattcag tagtaagtct cagaggctga aatgttctag gcctatatta	1020
gattgtatgg atgctagaag cttccaggcc taggcctgga agtagtttga acagagaaag	1080
aaatgccatg ggctcagccc aaactgtgta ttcgtatata ttgggtacgg ttctcctctc	1140
atccttccat ctgaagaaat aaaagttact ttacacata gtttttttat gtgggtgcta	1200
gaaacttgaa ttcagatcct tgtgtttgga gaacaagtcc tttactgact gagccgcttt	1260
gtctgccttc ctggtgacca tttgaatctg tgtccacttc acatgacatc agttgtgcca	1320
tctgtaaaat tgcaccagac tgtttgttgc aagaattgag aggggtttta tggtagaagc	1380
tgggaagctg ggaggaggga gctggaagga ggaggattgc tcaaccttgg tccaggaaac	1440
agtgatcatg tgatcctggt cctgctcctt cccttcctct tatggaggaa gttgtgtgtt	1500

RTS-0396**-34-****PATENT**

gctccatacg	tttgtgaccc	tttttttttt	ttttttttta	tcttgttatt	cctgccagta	1560
caaatgcaag	gaagatagtt	ggggagatgg	ctctgtggat	aagagtgagc	tcttgatgct	1620
aaagaatgaa	gatctgagt	tgaatctcta	gcacccatgt	gaaaaagctg	catggagatg	1680
cgtgctaacc	tttagcacca	gcagtgagt	agtgggacag	agtcagcagg	gggcaggggc	1740
ttgttggctc	tcaattgagg	ttcagcgaga	tcgtctggaa	aggaatcag	gctgcgggta	1800
acaaacccga	aacctgatgt	tcttctcggt	cttctgcata	tgtgctgccc	cccccccccc	1860
tggccacgtg	tgtcacacac	agtcttgcat	acacaagata	aatttaagga	agtgttttgt	1920
aaagtgtgt	atTTTTTgga	tccttttaac	atcagcatac	tttgttaaata	taaggtgaaa	1980
ggaagtggag	atgtagcttg	gcgaacacaa	ggtcagacat	agaacagcaa	ggagtctaga	2040
gggttaacac	agtctattgt	tcattggagct	ctgtgggagg	agcctgtaac	cctagcttgt	2100
tagaagtgag	agcagcaaca	tcaggatgtt	ggagctcaag	agaatgcttg	ctgttggact	2160
gtagagatgg	ctcagcagtt	aagagcactg	actgctcttc	cagatgggtcc	tgagttcaac	2220
atccagcaac	cagtagtata	tgtgtgtgtg	tgtttgtgtg	tgtgtgtata	tatatatatg	2280
tgtgtgtgtg	tgtgtatgta	tatgtgtgtg	tgtatatata	tatatatgta	tatatatata	2340
tatatatata	tatatatata	tatatataat	cttaaaaaaa	atgaatgctt	gctgttcttt	2400
tagaagacct	atgtttgggt	cccagcactc	agcatcaagc	agccacgcta	cctggaactc	2460
cacgtggagg	ggatctgatg	ctctcttctg	gcctctgatg	gctacagctc	ccccccatcc	2520
ccaatacaca	cataaataaa	atataaatac	acataataaa	aagaaatcta	aacaaattag	2580
attaagggtta	ctttgtgctt	acccttggct	acacggggag	ttcaaggcca	ggtttggata	2640
catgaggcct	tgtgaaaaca	aacacagcca	aacacttcaa	aaacaaatgt	gggcacaggc	2700

RTS-0396

-35-

PATENT

tgctcttgca gaggacctta gttggttctc agcaccacaca tgggtggctca cacacacctg 2760
taactccagt tccaaggaac ctatcactct ctgtggctcc cacgggcatg aactcatgt 2820
ggcagacatg tggatagata actagaagta acaagacaaà aaccaaact agcactgggt 2880
ctctttgtcc catttcccaa tgtgacccca ttgaataagt ctttcttttc tgcccttctc 2940
tattaaaaag gaatctttaa acctaacaac agcatgaggg ctataggtca tactacagaa 3000
aggaggggga tgctagcatt ttgttgcaag tacagtgaag cttgtcaaact gcttaaaaga 3060
ggggaaagaa gataccttcc cgccaggcca gggagaagtg cacagagaag acgagtccat 3120
cctgccattt gatgatcgta gtggggttgt caggctcccc ctccagagtg atgaacttac 3180
ctgtgagggg cttcataagg atttgcaccc cacctttgag atgaagcagg tatagggaac 3240
atccctccgg gatgttttag tcaacttagg catggccatc ttctagtctc ttactggcaa 3300
aggtcgatct ctctgggtt gggttggaga tgccttgggt ctctgctgtg acatgggtgt 3360
ttcgtggggc tcaacttcta gggatgtagg ttgcccagtt aaggattttt ctttctcact 3420
cgtgtttttt gtatgcatat gtgtgcacat gagtgctgga gccacagag gccagacgag 3480
gacatcacat ctctggacc tggagtttat aggtgtctgt cagccccgtg atgtgggtgc 3540
tggagatgaa ttctgccaga gcagtaagca gtcttaactt ctgagccatc attgtcagtg 3600

atgggtgtag cagtcctcac agaaacacag ctctgatctc aatggatata actccaatat 3660
cagacttctg aggcagggtt tcatgtagct caggctgacc gagaactccc tatcgtagct 3720
aaggatgacc ttagactcct gagcctcagg cttctacctc acaaatgatt atgattacag 3780
ctgtgtgctt tgccctgctt aatgatactg tattgtgggc tgaccagatg gctcactggg 3840

RTS-0396

-36-

PATENT

taaaggaact	tgaagccaag	catgaggagc	tcaggtaa	atctctgggac	ccacatggta	3900
gaagaaacct	gtggaaacct	gataagcttt	ctgctatatt	tactgaggta	ggctctgtta	3960
ctgaacccga	aacaagattg	ggggagggct	agatcctctg	tctctgtctc	atgtttttgt	4020
ttgtttgttt	tttgtttttt	ggtgttttga	gacaggggtt	ctctgtatag	tcctggctgt	4080
cctggaactc	actttgtaga	ccaggctgtc	ctcaaactca	gaaattcacc	tgcctctgcc	4140
tcccgagtgc	tgggattaaa	ggcatgcgcc	accacacccg	actctctgtc	tcattgtttg	4200
atcacaggag	gccaccatac	ctgcccattc	tttatgtggg	ccccttgcc	gtagagcagg	4260
taccacatcc	attgagtcac	gtctcagccc	ctgaacccat	tttcatccag	tcattctggg	4320
acaagcatct	aggctgctcc	tatttcttgc	ctgctgggtt	ggcacagggt	cttgtgcagc	4380
ctatgtgcct	gggttcctga	cagtcagggt	caaaagaaac	cgaggacaaa	tagctgactc	4440
tgaagtctat	tatcatacca	aagtgcacgc	tggcctgaat	actctttcag	taccaccagc	4500
acctgttaca	tcttctctgc	tcttctcacc	tcacccttac	cctaaacttc	ttcagcta	4560
agtcttctcc	tagcttttta	tcctatagt	actctgccat	ttcagccatg	catcctttgg	4620
atgtgtttct	ctctctctct	ctctctctct	ctctctctct	ctctctctct	ctctctctct	4680
ctctctctct	ctctctctct	ctctcggatc	tctctcctct	ttctctctca	ttctcccctg	4740
ctgtctttcc	tctaattggc	cagctcggtt	tactgaacat	gttagtctc	tctctccctc	4800
tgctctgctc	tgtctgtctg	tctgtctgtt	tctccctgct	ctggaccctt	ctagatgtct	4860
ctggctgtac	tctcccttgt	atctacaata	acaccccccc	ccaatgccag	tgtactgggtc	4920
atgtcctcag	tgtatacatt	ggccatccta	cctccaccat	ccatacctct	caagtgcagc	4980
gcatgtcaca	ctaggcaagc	actctaccaa	ctgagccgca	ttcccaacct	cagattttct	5040

RTS-0396

-37-

PATENT

tagtcagtat ttttttttta atattagcaa ataaattagc agttttcagg gtggggagaaa 5100

tatcacagtg gtgaagaaca cttgctgctc ttggagctga tggaagttga gttcccagca 5160

cctacacaag acagctcatc cacctctaac tcagtactag agaatcctat tccctcctct 5220

gacctcctag ggcacagaca caagcacgga acacatacag agggatatat gtaaacaata 5280

aaaataatth taccaaatgc tgggtttcat tatgacatta tcacacacat atatcagtat 5340

ccgtagctca tatttacctt ccattaacct ccttgtccct cctccctctc ctactgggcc 5400

catgcagacg tgtgtgtggt atttatgtat ccgtccctct actgtgagag aaaacatgtg 5460

atgttgtctt tttttcatta cctctcttgt tgtccctctc cctcagtcca ttccacatgt 5520

aattctactt tcaagactta tagatatttt acatctgaac ttcacgtgag agaggacacg 5580

tgacacttgc tttctgagtc ttgcttgctt tgcctaacat ggtgctgtct agttccattc 5640

atctttctgc aggtgaaatc tcttcattct tctccacagc ttcattcacc attccgtagt 5700

gcatagatac catgctttct ttatctgttt atctgctggg tccattcctc agccactgtg 5760

aacaatgcag cagtaaacad ggatgtgcat gtatgcacat ggctggctga ctgactcctc 5820

taggtatata tagagtggta tagctggatc atatgctagt tctaatttta attgctttaa 5880

ttcctttgct gtgtatgcat acacacgtgc acatgtgcat gtatgcactc agataagggtg 5940

tgagagcggg cacgtgtgac ctatagatgt cagagaacag ctttgtgaag ttggttccct 6000

ccttccactt cctgtggggt ctagagattg gcatgagatc aggcttgtgc agcaaaccat 6060

cttgctagct ctgattataa ttaaaaaaaaa aaacttttta tagtggactg gagaaatgac 6120

tcagttgtta agagcattca ctgttcttag agaggaccag ggttcaattc ccggcacaca 6180

RTS-0396

-38-

PATENT

tgtggtggat	cacaactatc	agtagttacg	catgagttgt	acacacatac	acgagggcaa	6240
cgcactcatg	tacataaaat	aaaaataagt	aaatctttaa	aaaaaaagct	tacatatata	6300
ctggtggaag	tgtatctggg	ggaaaagaga	ccgagaagat	agcccacaaa	acaagcatga	6360
gggcctgaat	tcagatcccc	agccacctca	taaaaaccca	tgggcatgtg	aggcaaaggc	6420
agacgggatca	ctccaagttc	aaggatcatcc	tggtgtacat	agcaagtttc	tagccagcca	6480
gggctaccta	gagaatcctt	ttctcaaaaa	gaaaaaagaa	agtgaaaagc	gattaaggaa	6540
gatgtacaat	gttaatctct	agattccaca	tgcgccacac	acaggagccg	ggtgagacta	6600
ggggtatatc	tcagagatag	aacactccct	agcctataag	gaccctaagt	tccattccta	6660
gcacaaaggt	gggggatggt	aatgatttta	tgataatatt	tccataactt	tcctttgtct	6720
tttgtatgta	ttactgtctg	tgtgcattca	gccagttcaa	aacgcagaca	gttgacatgt	6780
ttccagccag	ttaagtaagt	taacatgggc	ctcctgttct	gtggttaccc	actctctaca	6840
tgtgcataca	gcaggagaat	ccaacacttt	tcaacagaaa	ctccaattac	cagacagcat	6900
caagaattct	cctttgattg	acagaaatat	ctgtcatagc	aaccttgtca	ccagggaac	6960
aagttatcat	tgaacacaca	gccagtcaga	agcttcattt	ctggggaaga	tagcaacagc	7020
ttccaagtgg	tcctagccac	ttttgtccaa	atgaggcatc	atggacagag	gggtgtcagg	7080
ggggagagta	agccagcaag	agttctactg	ttgaaccaca	ttgtacatct	cacccttggt	7140
tcctctcatt	ctgatgacag	aactgagagg	ctatgacaga	ccccatggac	acaaaaccag	7200
gtgcttttac	atttgacctt	tgaaaggaag	tttctcacct	caggtctcca	gcaatgcctg	7260
ggaatggaga	cccccaaagc	agctgtgtac	tatgttggcg	atggccacta	aagtcgcatg	7320
aacacagaag	ccaggtggga	ggaagagcac	atcacctgaa	tccacttatg	ctgaagagga	7380

RTS-0396

-39-

PATENT

aagagacaaa tcttgacagg ggtgggggtg gggaggctta gttcagttag agtgcctggc 7440

aggcacaaaag tcctgtgctc aagtccctga agtacagaaa ccatgcacag tgggtgcgtcc 7500

ctgccacccc agcatcgaga atgcaggatg gtcaggagtt caaggtcgtt cttggctaca 7560

cagttcaaac ttgcatagct tacaaaagag cttggattca atgaataaat agatagataa 7620

ctaaataaag attaaagtct tttcatttgt ccaatttata aacttcctct gctaattctca 7680

attttgtcct atctagttaa aagacatcga ggccagtgtg acagcttcag agccggacag 7740

cctgacgtta acaccagga tttgcatagc cacctccagt tgtcctcacc tccgtatgca 7800

catcacactg tggcgtgcac gcacttacac ccacacgtgt cacgcacatg caataatgac 7860

taaataatgt ttttaaagac agagaagata aggcagattc tattgagtca ttcacacaca 7920

taaatattct gtatgtgggc cggagctatg actaccaag atttattatt ttaattactt 7980

gttgagaaaag agggatttcc aaaggagacag gcccttgct ctttgcacca gaaagcagaa 8040

agcagaaaagc agaaagcaga aagcagaaaag cagagctctt gcctagactc ctccagtgg 8100

atgttttggg taatggctgg gaacctcctt tctcagtggg tcctttctca gtggtagagc 8160

tcttgcttag cccaccccc accccgcccc cagagagggg ctgggtctct agctctgtgg 8220

tagaccatct gtatagagca taccactgag aggctggaga catgggttcag aggtagggtta 8280

cctggctgga attccatagt gagggctctgg tgggtgtggtt cagcaagggg gcagttgact 8340

agatttttagc tggtagagct tgcctacact gtatatcccc gccaaacata gaaacataca 8400

tgacagctgt ggtcacacag ggaccgtgtc tcagtttgca tctccagccc tacagggtgaa 8460

gtcttggtc ctagccttgc ccctcccacc atggtccttg gtgttatctc cagacaacgt 8520

RTS-0396

-40-

PATENT

cctgagaaga	caatccttct	aatgtaggaa	gggctgagca	ggagggaaat	ccctcctctg	8580
ggacctctag	agttcacctc	tcttggggtc	agatgtggca	atggaaggcc	aggggccagg	8640
gtacttatta	tccaaggcag	gatgggccag	aagtcaacaa	gaaggagctg	tgggacagga	8700
gctaataccc	agaactgagt	tgtgtcctgc	taagtcctct	gccacggtaa	gtgatagcca	8760
tccccagtc	agagtgtga	tgtggcggcc	ccagagctgc	tgaatgtcca	tccatgtgtg	8820
ccctcaggaa	ctaaaggaca	ttgcagtctg	actccccag	catgggaagg	gtctggtcta	8880
aggcggggct	cttgcttgtc	tcttgagta	cccacgggat	gaagaacctt	tcatttcccc	8940
tccttttct	tttcttctt	gtccctgaac	tgctgggctc	cagcatgcca	ctgtgtccca	9000
tcgatgaagc	catcgacaag	aagatcaaac	aagacttcaa	ctccctgtgt	gaggatcccc	9060
ccttcgcccc	catccaacct	tgccgagggc	cttacagact	tatccctgat	ggggaacaga	9120
cccgcccagc	tacaaggcta	ccctcagcct	cagcctcacc	ctgttccaac	ccaaattcat	9180
cctgacctac	cttgatcatg	gttcacccca	caacttagct	tcttccaacc	atcacctcca	9240
aacctcccct	cactccaaaa	ggccccacac	tgtggtccat	ggagctgagc	ccccagtgcc	9300
tgacctctt	gcctcagcct	cctgagtgtt	tggagtacag	gtgtgagcaa	aatattttac	9360
cgtgaacgtg	tgctgtccat	gtctgtgtat	gtgtgtttat	atatgtggtg	cacatatgtg	9420
aaggagcttg	tgtgtgcata	ggcatatgga	gaattgaagt	tgggtgtagtg	ttatcattcc	9480
acctctgctt	tgttgagaca	gaatctctca	gctgaacca	gggcttggtg	gtttgtggta	9540
gtctagttag	ccatcttggt	ctggggactc	catgtctgtc	tgccctctgg	aggctgggat	9600
tatgggtgcc	cctacaccat	gcatgcctag	cttctaaatg	ggttctgggg	atcttggtct	9660
tgatcctccc	acttgtgagt	caaactcttt	agctataagt	caccttctca	ctctgctgag	9720

RTS-0396

-41-

PATENT

aagaatttga cctcactgtc agtgtcaaac ccaaagatcg cccctgcaa agatgcagct 9780

ggattacccc ttcaatcttc cttctgcag ttccaatgc aataaagaac attggcttaa 9840

attgctggac agtctcctcc agagggaagt tggcctcctg ccagaaggt gagtgcaaac 9900

tctgtgttc agactttctg gaagttctga aactcctctg tctgccttgt ctgggtcctc 9960

aacatgtctg tccttaggac tccctcccag acttcagtc ttctcatctc ccagcccagc 10020

tcaaggctct ttagactcct gctgtatcat cttgcactct gtttccgtgg caacagcctc 10080

cagccccctc ccccatctct gctcccacc tgccacagtc ttccggtttt tcagggactt 10140

ctttccttgc aggcacagca gtcttgagct gctcctgtgg ctctgcctgt ggctcgtggg 10200

acattcgtga agaaaaagtg tgtcactgcc agtgtgcaag gatagactgg acagcagccc 10260

gctgctgtaa gctgcaggtc gcttctgat gtcggtcagt tgagaactga gcttgcctt 10320

cttatgttga cagggacggg gaggaggcag gggcaggctc aagctgaggg tctggaaatg 10380

aagaatgaga agatggtgat gatgaagatg gatggcgaag tgggcatggg ccttgtgtga 10440

cttctttagt ggagaagggt gtgtgtggga attgtgtggg aaatgttgca cagtgttgtg 10500

aattttacta cttgtccatc actccttttt tcttctcttc ccttcccct tcctctttga 10560

gactctcata tagtccaggc tggcctcaaa tgatagtcac catcacagag gagactggac 10620

cttggcagga ctgaggttcc atagctctca agttcacttt tcacctctgt ggatatgatg 10680

tcgaatacct attttcaacc agaggcacc agggcattta caccacctgg ggcagaggat 10740

atcgttttcc ttgtatcttg agcttagaat aaggatatagc ctgggtgcta gtaactgtct 10800

atagaatgag ggctggtgag atgattcagt gggtaaagat gctgctgcca aggctgatga 10860

RTS-0396

-42-

PATENT

tcagggttg attcctggaa actacatggt ggaaggagag agtccagggt gtcttccac 10920

ttccacatgg gactgagggc acttgagtac cacgtgtgca cacacagtga atgaaagagt 10980

gaatgaatga agcaataaaa gtatctgatg agcctggcat ggtgacacat gcctttaatc 11040

aaagcacttg caaggcagag acaggtggat ctctgtgttc aaggccagct ggtctacaga 11100

gaaaaaaaat ccaaagaaa gagaacgaaa gaaagagaga gggagggagg gagggaggag 11160

ggagggaggg agggaggagg aaggaaggag gaattcaaan nnnnnnnnnn nnnnnnnnnn 11220

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 11280

nnnnnnnnnn nnnnnnnnct ttctcttccc ttctgtccc tcctgatcag caccaggagg 11340

gaggaaggaa ggaaggaagg aatcaaatta gtaactgcaa tggttaacag atctagaatt 11400

acctagaaga cacgtatctg ggcattgcctg gaaggaggtt ggttaattgg ttttaattcaa 11460

gcgggaggac cctgattgaa taaaaggag aaagtgggag ttggagagaa ttcagagaat 11520

taagaacact tgctgtcct gcaagggacc caaccagtt ttccagtacc tagtttggac 11580

agctgacagt catctttaac tcatatgccc atacacactt atacaccccc ccacacaca 11640

cacacacact cacacactca cacatactca cacacacaca catactcaca cacacattca 11700

cacacacatg cacacgtatg caaaccagca atggcacctg cagagatggc tcagaagtta 11760

agagcacttg ctgttcttcc agaggactga gttcatttcc cagcactcaa atgaagtgtg 11820

tcttagttag ggttaccatg accaagaaac aagttggaga ggaaagggtt tatttagctt 11880

acatttccat actgctgttc atcattgtag gaagtcaaga cacaaactca cacagggcaa 11940

gaacctgtag gcagagctga tgcagaagcc atggagggat gctgctcact gacttgtggc 12000

cctgctttg ctcagcctgc cttcctatag aaccaggac caccagccca gagattgcac 12060

RTS-0396

-43-

PATENT

tagacacaat gagctggggtt ctctgccact gatcagtaac tgagaaaatg ccctgtagtg 12120
gatcttatga aggtatttcc tcaattgagg cacttcctct gatgactcta gcttggtgtca 12180
atgagacgca aaaccagcca gtacagagtg actcaagacc atctgtatct ttggctacag 12240
gagatttgac acctctgacc agtgcagtga cctgtactta tgcacaaata cccacattta 12300
gatacaaaca ttccttcaca taatcaaaaa gaatacaata taagccgggt gtagaggcac 12360
acatcttaaa tcctagcact cgggaggcag aggcaggtgg atttctgagt tcaaggccag 12420
cctgattctc agagtgagtt ccagaacagt gaaaactaca cagagaaacc ctgtcttgaa 12480
aaaaaaaaaa aaacaaacaa ccagaaaaca aagaaacaaa gaaacaaaaa ccaacaaaaa 12540
aagaaaaaaaa gaaaaaaaaa aaaggaagaa aaatttaggg gccagcaaga ggctcagtgg 12600
gtagaggctc ctgctaccaa gctgaccatt tacacatatg tacacaaaat aaaataaatt 12660
taaagttaaa aaataaaaaat tggggcctaa ggaaagatgg gtcaatgggt aagagcatgt 12720
attgcttttt caggggaagt gagcgtgggt tccagcacag ccaccgttc ctgtagctcc 12780
agagatgtct gatgtcctcc ggtctctaca ggcacctgca ctcacgtgcg cgaatccaca 12840
cacaagcaca catacttaaa aataaaacaa aacaggctgg atgtgggtgg ctcatacttt 12900
taattccagt acttggaac tagagacaga ctgttagttt atggccatcc tggcttgggg 12960

gatggctcag tggtagcag cactgactgc ccttctaaag gttcaatccc aagccatcag 13020
taatctatgt cgggctggag aggtggctca gcggttaaga gtactgactg ctcttcctga 13080
ggctctgagt tcaattccca gcaaccacgt ggtggctcac aaccatccta tgcccccttc 13140
tgggtgtgtct gaagatagct acagtgtact catatacaaa aaataaataa taataataat 13200

RTS-0396

-44-

PATENT

ttttttaaaa aggtcatcct ggtctaccta gccagtgcta catagttcca atgaattaag 13260
aacaaatgga atattttaaa ttgtctttga tattgaaagt tgttctcttt aattttttat 13320
ttattcactt tacatcctgc tccactgcca cccttctggg tgccccgttc cacaatcatt 13380
ctcccatctc ctctcctct aagtgtgtgg ggccccctag gtatacccct accctgttac 13440
ttcaagtctc tgtgggggcta ggcacttcct ctcccactga ggccagcaga ccagacagct 13500
cagctagaag actacagccc acgtacaggc aacagctttt ggaatagctc ctgctccagc 13560
tgtttgggac ccacatgaag acccaagctg cccatctgat atatatgtgg ggggaggcct 13620
aggtccagtc tattatattt ttgtgttttg tttgtctctg ggtatcttca aatgtctgtc 13680
cagcccgaag atttcaaagg aaataaatct ctggccagag tttaacacac cacaataaac 13740
ctaaatccac ctagagtcct ccaccagttt catggttgaa ccttcaccac agccaattag 13800
agagagtagc agataagcca acgatgagaa gtgaagacag cggaatgtc cagtcagttg 13860
tgggtctcat cctgctcttc ttctgggtg agagtgcagc tctgacagac actgagactc 13920
acacagtgga tggttttctc agaggaagaa gacatatgcc cactggcact tgagtctgtt 13980
actggctgtc gtgatgggca atgcaattca ccatttccca gggagcaaga acggcaagca 14040
cctttgtgta tccagttctg cctctctcca ttgcgcataa accgctttcc ttcattcttc 14100

atttcctcac tgcacacttg ttagcgtcta ccacctactt actcacttcc tgggtgcaact 14160
gtgcctggcc agggctgggc tcagggttgt ggtattgtcc tgggtacttcc tgacgcacca 14220
gggtggaaag ttgttttcat acagtatatt ctgatcaggc tttcccttcc tatctcctcc 14280
catcttccca cccatgaacc cgcccttctc tctcaaacag gcagacaaga aacaaacaaa 14340
caaacaaaca aacaaaaaac tgaaaacaaa aaaaaccac caacctcccc ccccaaaccg 14400

RTS-0396

-45-

PATENT

gcataataat ttaaaaagaa aaagtacaac aacacgcacg cacacacaca cacacacaca 14460
tacactcaaa caaccaaacc aactcaaac cccaaaactt aaaaaaaaac ccaaaccat 14520
aaaacccac aaaattggga accataatgt ataagcaaaa ggcccagtaa acataacaca 14580
ttacaaaaaa ttatgaaaca aaaactttac taagtgtgtg tcataaagcc tataagattc 14640
ctttgaagta aactaat tcttttgcaa gccattgttg tcaagtgatt aggggtggct 14700
gcccattgtc acttccccct ctctgtgctg ggactccggc tggctcgaac ctgcacaggt 14760
cctgtgctgc tgctacagtc tctgcgagtt catgtgtgtg tgagtcttgt atagcttgga 14820
agacactgtc tcttggtgc catccctagt tcttatgac tcttctcttc tgtgtagctt 14880
cctggatcct gatggggagg gtctgatgaa cacattccat ataggactaa gtgtactaaa 14940
atctatcact ccacgcactg tccagtaaag ggtactaagt aagctcccat ctgctgcaag 15000
a 15001

<210> 54

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 54

attagctcct gtcccacagc

20

<210> 55

<211> 20

RTS-0396

-46-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 55

gggtattagc tcctgtccca

20

<210> 56

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 56

actcagttct gggtattagc

20

<210> 57

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 57

ttagcaggac acaactcagt

20

<210> 58

<211> 20

RTS-0396

-47-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 58

gaggacttag caggacacaa

20

<210> 59

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 59

ggcagaggac ttagcaggac

20

<210> 60

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 60

tgggtacgtg gcagaggact

20

<210> 61

<211> 20

RTS-0396

-48-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 61

tcatcccgtg ggtacgtggc

20

<210> 62

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 62

aaggttcttc atcccgtggg

20

<210> 63

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 63

ggaaatgaaa ggttcttcat

20

<210> 64

<211> 20

RTS-0396

-49-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 64

gttcagggac aaggaagaaa

20

<210> 65

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 65

agcccagcag ttcagggaca

20

<210> 66

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 66

ctggagccca gcagttcagg

20

<210> 67

<211> 20

RTS-0396

-50-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 67

gcatgctgga gcccagcagt

20

<210> 68

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 68

cagtggcatg ctggagccca

20

<210> 69

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 69

atcgatggga cacagtggca

20

<210> 70

<211> 20

RTS-0396

-51-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 70

cttcatcgat gggacacagt

20

<210> 71

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 71

tcgatggctt catcgatggg

20

<210> 72

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 72

gatcttcttg tcgatggctt

20

<210> 73

<211> 20

RTS-0396

-52-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 73

gggagttgaa gtcttgtttg

20

<210> 74

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 74

acagggagtt gaagtcttgt

20

<210> 75

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 75

gaaacagga gttgaagtct

20

<210> 76

<211> 20

RTS-0396

-53-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 76

gcatttggaa acagggagtt

20

<210> 77

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 77

ttattgcatt tggaaacagg

20

<210> 78

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 78

ctttattgca tttggaaaca

20

<210> 79

<211> 20

RTS-0396

-54-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 79

gccaatgttc tttattgcat

20

<210> 80

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 80

caatttaagc caatgttctt

20

<210> 81

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 81

gcaatttaag ccaatgttct

20

<210> 82

<211> 20

RTS-0396

-55-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 82

tgtccagcaa tttaagccaa

20

<210> 83

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 83

gagactgtcc agcaatttaa

20

<210> 84

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 84

ttccctctgg aggagactgt

20

<210> 85

<211> 20

RTS-0396

-56-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 85

gcccaacttcc ctctggagga

20

<210> 86

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 86

ggccaacttc cctctggagg

20

<210> 87

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 87

caggaggcca acttccctct

20

<210> 88

<211> 20

RTS-0396

-57-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 88

gggcaggagg ccaacttccc

20

<210> 89

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 89

actgctgtgc cttctgggca

20

<210> 90

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 90

cacaggagca gctcaagact

20

<210> 91

<211> 20

RTS-0396

-58-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 91

gtcccacgag ccacaggcag

20

<210> 92

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 92

atgtcccacg agccacaggc

20

<210> 93

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 93

cttcacgaat gtcccacgag

20

<210> 94

<211> 20

RTS-0396

-59-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 94

ctttttcttc acgaatgtcc

20

<210> 95

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 95

cactggcagt gacacacttt

20

<210> 96

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 96

tgcacactgg cagtgcaca

20

<210> 97

<211> 20

RTS-0396

-60-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 97

atccttgac actggcagtg

20

<210> 98

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 98

gtctatcctt gcacactggc

20

<210> 99

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 99

tgtccagtct atccttgac

20

<210> 100

<211> 20

RTS-0396

-61-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 100

ctgctgtcca gtctatcctt

20

<210> 101

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 101

cagcgggctg ctgtccagtc

20

<210> 102

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 102

acagcagcgg gctgctgtcc

20

<210> 103

<211> 20

RTS-0396

-62-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 103

cctgcagctt acagcagcgg

20

<210> 104

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 104

cgacctgcag cttacagcag

20

<210> 105

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 105

ggaagcgacc tgcagcttac

20

<210> 106

<211> 20

RTS-0396

-63-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 106

tcaggaagcg acctgcagct

20

<210> 107

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 107

tccccgacat caggaagcga

20

<210> 108

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 108

ctcacttccc cgacatcagg

20

<210> 109

<211> 20

RTS-0396**-64-****PATENT**

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 109

gctggaaacc acgctcactt

20

<210> 110

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 110

ctgtgctgga aaccacgctc

20

<210> 111

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 111

tacaggaacg ggtggctgtg

20

<210> 112

<211> 20

RTS-0396

-65-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 112

catctctgga gctacaggaa

20

<210> 113

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 113

gacatctctg gagctacagg

20

<210> 114

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 114

atcagacatc tctggagcta

20

<210> 115

<211> 20

RTS-0396

-66-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 115

aggacatcag acatctctgg

20

<210> 116

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 116

agaccggagg acatcagaca

20

<210> 117

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 117

tgcttgtgtg tggattcgcg

20

<210> 118

<211> 20

RTS-0396

-67-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 118

tgtgcttggtg tgtggattcg

20

<210> 119

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 119

tatcacttac cgtggcagag

20

<210> 120

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 120

atggatggac attcagcagc

20

<210> 121

<211> 20

RTS-0396

-68-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 121

cccgtgggta ctgcaagaga

20

<210> 122

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 122

acgttcacgg taaaatattt

20

<210> 123

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 123

gattctgtct caacaaagca

20

<210> 124

<211> 20

RTS-0396

-69-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 124

cccagaaccc atttagaagc

20

<210> 125

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 125

actgctgtgc ctgcaaggaa

20

<210> 126

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 126

ctcaactgac cgacatcagg

20

<210> 127

<211> 20

RTS-0396**-70-****PATENT**

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 127

cataagaagg acaagctcag

20

<210> 128

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 128

ctccatggct tctgcatcag

20

<210> 129

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 129

cataagatcc actacagggc

20

<210> 130

<211> 20

RTS-0396

-71-

PATENT

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 130

taaccattga cccatctttc

20

<210> 131

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Antisense Oligonucleotide

<400> 131

ctcacttccc ctgaaaaagc

20

<210> 132

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 132

cctgcaggat gaaagctctc

20

<210> 133

<211> 20

<212> DNA

<213> H. sapiens

RTS-0396

-72-

PATENT

<220>

<400> 133

gaaagctctc tgtctcctcc

20

<210> 134

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 134

gaagaagcca tcaatgagag

20

<210> 135

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 135

caatgagagg atccaggagg

20

<210> 136

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 136

ggatccagga ggtcgccggc

20

RTS-0396

-73-

PATENT

<210> 137

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 137

aggaggtcgc cggctcccta

20

<210> 138

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 138

aggtcgccgg ctccctaata

20

<210> 139

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 139

gcaataagca gcattggcct

20

<210> 140

<211> 20

<212> DNA

<213> H. sapiens

RTS-0396

-74-

PATENT

<220>

<400> 140

ataagcagca ttggcctgga

20

<210> 141

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 141

cagcattggc ctggagtgcc

20

<210> 142

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 142

ctgtggctcg tgggatgtgc

20

<210> 143

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 143

tcactgccag tgcgcgggca

20

RTS-0396**-75-****PATENT**

<210> 144

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 144

gtgcagccct gaggtcgcgc

20

<210> 145

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 145

gctccaggtc cggagggggtt

20

<210> 146

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 146

ggggagctgg aaataaacct

20

<210> 147

<211> 20

<212> DNA

<213> H. sapiens

<220>

RTS-0396

-76-

PATENT

<400> 147

ctggaaataa acctggagat

20

<210> 148

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 148

aataaacctg gagatgatga

20

<210> 149

<211> 20

<212> DNA

<213> H. sapiens

<220>

<400> 149

acctggagat gatgatgatg

20

<210> 150

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 150

agtctctctgc cacgtaccca

20

<210> 151

RTS-0396

-77-

PATENT

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 151

tgccactgtg tcccatcgat

20

<210> 152

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 152

ttggcttaaa ttgctggaca

20

<210> 153

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 153

ttaaattgct gacactctc

20

<211> 20

<212> DNA

<213> M. musculus

<220>

RTS-0396**-78-****PATENT**

<400> 154

tcctccagag ggaagttggc

20

<210> 155

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 155

aaagtgtgtc actgccagtg

20

<210> 156

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 156

tgtgtcactg ccagtgtgca

20

<210> 157

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 157

gccagtgtgc aaggatagac

20

<210> 158

<211> 20

RTS-0396**-79-****PATENT**

<212> DNA

<213> M. musculus

<220>

<400> 158

gtgcaaggat agactggaca

20

<210> 159

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 159

aaggatagac tggacagcag

20

<210> 160

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 160

gactggacag cagcccgtg

20

<210> 161

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 161

RTS-0396**-80-****PATENT**

ggacagcagc ccgctgctgt

20

<210> 162

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 162

aagtgagcgt ggtttccagc

20

<210> 163

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 163

cgcgaaatcca cacacaagca

20

<210> 164

<211> 20

<212> DNA

<213> M. musculus

<220>

<400> 164

cgaatccaca cacaagcaca

20

<210> 165

<211> 20

<212> DNA

RTS-0396

-81-

PATENT

<213> M. musculus

<220>

<400> 165

tgctttgttg agacagaatc

20